 
 
J3 Bioscience, 
Inc. Clinical Investigation Plan and Protocol CI03  
CI03 -CIP 
Rev. 0 2 
Page 1 of 60 A Clinical Investigation to Evaluate Efficacy of the J3  
Bioscience Lubricating Intravaginal Ring, VR101, as a 
Personal Lubricant Device in Women  
  
CI03: A Clinical Investigation to Evaluate Efficacy of the J3 Bioscience 
Lubricating Intravaginal Ring VR101 as a Personal Lubricant Device in 
Women  
Original  Date:  July 10, 2019  
Revision:  Rev 0 2 
Revision  Date:  January 31, 2020  
Effective:  January 31, 2020  
 
SPONSOR:  
J3 Bioscience, Inc. (J3 Bio, formerly named ViroPan, Inc.) 
[ADDRESS_769159], Suite N231  
Salt Lake City, Utah [ZIP_CODE] 
Email: [EMAIL_11139]  
Mobile: 801 -550-9956  
Office: 801 -931-4756  
Fax: 866 -768-9341  
 
OFFICE ADDRESS:  
J3 Bioscience, Inc.  
[ADDRESS_769160], Suite N231 
Salt Lake City, Utah [ZIP_CODE] 
Email: [EMAIL_11139]  
Mobile: 801 -550-9956  
Office: 80 1-931-4756  
Fax: 866 -768-9341  
 
 
AUTHORIZED REPRESENTATIVES (for studies conducted in the EU or elsewhere): 
For studies conducted in the EU: ProMedt Consulting GmbH  
 
CONFIDENTIAL INFORMATION  
 
 
This protocol is for the sole use of the intended recipi[INVESTIGATOR_190852]. It contains CONFIDENTIAL, 
PROPRIETARY, and PRIVILEGED information. Unauthorized review, use, disclosure, copying, or 
distribution is strictly prohibited.  
 
 
J3 Bioscience, 
Inc. Clinical Investigation Plan and Protocol CI03  
CI03 -CIP 
Rev.  [ADDRESS_769161] the investigation. Documentation of my 
qualifications and professional affiliations are contained in my Curriculum Vitae.  
 
I will provide the copi[INVESTIGATOR_585027] -clinical and prior clinical 
experience (i.e., Investigator's Brochure) to all staff involved in this investigation. I will discuss this 
material with them to ensure that they are fully conversant with the medical treatment in, and the 
conduct of the investigation, and that they will handle the data and information generated in the 
investigation confidentially.  
 
I agree not to start enrolling participants until a duly appointed Institutional Review Board has issued a 
favorable opi[INVESTIGATOR_3078] n and the Sponsor has authorized the initiation of enrollment.  
 
I will conduct the investigation in accordance with the provided protocol, the Good Clinical Practice 
guidelines of the FDA, and the spi[INVESTIGATOR_585028], and the moral, ethic al, and scientific 
principles that justify medical research. The investigation will be conducted in accordance with the 
relevant laws and regulations relating to clinical investigations and the protection of participants in the 
country(ies) in which the in vestigation will be performed. All participants will be comprehensively 
informed about the nature of the investigation and of its investigational nature and that they may 
withdraw from the investigation at any time. They will give their written consent to participate before 
entry into the investigation. I will only use the Informed Consent Forms approved by [CONTACT_585056].  
 
I have read the Investigator's Brochure, including the potential risks of the J3 Bio investigational 
Vaginal Lubrication Ring VR101 and I agree to report all adverse events that may occur during the 
investigation.  
 
Where applicable, the information reported in the Case Report Forms (CRFs) will be transcribed from 
my records, reports, and manuscripts. Either  I, or an appointed person, will attest to the authenticity 
and completeness of the data and accuracy of the transcriptions by [CONTACT_585057]. I 
agree to the audit and monitoring procedures described in the protocol and contract, which involve  
verification of investigation records against original records and confirmation that the study is 
conducted in accordance with this protocol. I will make available additional background data from my 
records at the request of government regulatory agencies . 
 
I understand that I am obliged to provide to the Sponsor, for the Sponsor's unrestricted use, the 
complete results and all data generated during the investigation, and that all information concerning 
VR101 and the Sponsor's activities, such as patents, formulae, manufacturing procedures, and basic 
unpublished scientific data and information supplied by [CONTACT_1034], including the investigation 
protocol and all investigation results, are strictly confidential and the exclusive property of the Sponsor. 
I will undertake only to use this information to conduct the investigation and not to use it for any other 
purpose without the written agreement of the Sponsor. I will not make any changes to the protocol or 
propose changes to the protocol or any Sponsor -appro ved documents to the IRB or FDA without the 
written approval of the Sponsor.  
 
I will supply the Sponsor with the investigation data in such a way that the participant cannot be 
personally identified.  
 
 
J3 Bioscience, 
Inc. Clinical Investigation Plan and Protocol CI03  
CI03 -CIP 
Rev. 0 2 
Page 1 of 60 A Clinical Investigation to Evaluate Efficacy of the J3  
Bioscience Lubricating Intravaginal Ring, VR101, as a 
Personal Lubricant Device in Women  
  
Investigator  Signature:     
 
[CONTACT_257808]:    
 
Date:     
 
 
J3 Bioscience, 
Inc. Clinical Investigation Plan and Protocol CI03  
CI03 -CIP 
Rev.  [ADDRESS_769162] of Abbreviations and Definitions  
 
ADE Adverse Device Event (Effect)  
AE Adverse Event  
API [INVESTIGATOR_585029]01  Clinical Investigation 01 (Pi[INVESTIGATOR_2268])  
CI02  Clinical Investigation 02 (Pi[INVESTIGATOR_22735])  
CI03  Clinical Investigation 03 (Pi[INVESTIGATOR_22735])  
CHA  Clinical Hazard Assessment  
CRA  Clinical Research Associate  
CRF Case Report Form  
EC Ethics Committee  
FDA Food and Drug Administration of [LOCATION_002]  
FSFI  Female Sexual Functioning Index  
FSFI -LD FSFI Lubrication Domain  
GCP  Good Clinical Practice  
HEPA  High-Efficiency Particulate Air  
IB Investigator’s Brochure  
ICF Informed Consent Form  
ICH International Conference on Harmonization  
IDE Investigational Device Exemption  
IFU Instructions for Use  
IRB Institutional Review Board  
ISO International Organization for Standardization  
IVR Intravaginal Ring  
NCR  No Carbon Required  
NSR  Non-Significant Risk  
OHRP  Office of Human Research Protection  
PI [INVESTIGATOR_585030] (Effect)  
SAE Serious Adverse Event  
SOP  Standard Operating Procedure  
Sub-I Sub-Investigator  
[LOCATION_003]E  Unanticipated Serious Adverse Event  
VHI Vaginal Health Index  
 
 
J3 Bioscience, 
Inc. Clinical Investigation Plan and Protocol CI03  
CI03 -CIP 
Rev. 0 2 
Page 1 of 60 A Clinical Investigation to Evaluate Efficacy of the J3  
Bioscience Lubricating Intravaginal Ring, VR101, as a 
Personal Lubricant Device in Women  
  
TABLE OF CONTENTS  
Study Summary  ................................ ................................ ................................ ...........  10 
1 SYNOPSIS  ................................ ................................ ................................ .............  12 
1.1 Sample Size  ................................ ................................ ................................ ..........................  12 
1.2 Investigational  Devices  ................................ ................................ ................................ ..........  12 
1.3 Summary of Endpoints (see Section 5.1.1  for details)  ................................ ...........................  12 
1.3.1 Primary  Efficacy Endpoint  ................................ ................................ ...............................  12 
1.3.2 Safety  Endpoint  ................................ ................................ ................................ ..............  12 
1.3.3 Exploratory  Endpoints  ................................ ................................ ................................ ..... 12 
1.4 Summary of Study Schedule and  Study  Schematic  ................................ ..............................  13 
2 BACKGROUND  ................................ ................................ ................................ ...... 13 
2.1 Purpose  ................................ ................................ ................................ ................................ . 13 
2.2 Scope  ................................ ................................ ................................ ................................ .... 14 
2.3 Summary of VR101  Bench  Testing  ................................ ................................ .......................  14 
2.3.1 Bench  Tests/Stability  ................................ ................................ ................................ ...... 14 
2.3.2 Biocompatibility  Tests  ................................ ................................ ................................ ..... 14 
2.3.3 Summary of VR101  Preclinical Testing  ................................ ................................ ...........  15 
2.4 Summary of VR101  Clinical Studies  ................................ ................................ ......................  15 
2.4.1  Summary of VR101  Pi[INVESTIGATOR_16116]  ................................ ................................ ..............................  16 
2.4.2  Summary of VR101 Pi[INVESTIGATOR_585031]  (CI02)  ................................ ................................ ..... 17 
3 Identification and description of the  investigational device  .............................  18 
3.1 Summary Description  of VR101  ................................ ................................ ............................  18 
3.2 Principles of Operation  of VR101  ................................ ................................ ..........................  22 
3.3 VR101  Intended  Use ................................ ................................ ................................ .............  22 
3.4 Lubricating Agent  ................................ ................................ ................................ ..................  22 
3.5 Supplier of VR101 Devices and  Sham  Rings  ................................ ................................ ........  22 
3.6 VR101  Identification  ................................ ................................ ................................ ..............  22 
3.7 VR101  Lot Traceability  ................................ ................................ ................................ ..........  23 
3.8 Training and Procedures Required to use  VR101  ................................ ................................ . 23 
3.9 Sham  Rings  ................................ ................................ ................................ ...........................  23 
4 Objectives and hypotheses of the  clinical  investigation  ................................ ... 23 
4.1 Study Objectives (ECH  E3; 8.) ................................ ................................ ..............................  23 
  
J3 Bioscience, 
Inc. Clinical Investigation Plan and Protocol CI03  
CI03 -CIP 
Rev.  02 
Page 2 of 60 A Clinical Investigation to Evaluate Efficacy of the J3  
Bioscience Lubricating Intravaginal Ring, VR101, as a 
Personal Lubricant Device in Women  
 4.1.1 Primary Objectives of the  Clinical  Investigation  ................................ ..............................  23 
4.2 Hypothesis of the  Clinical  Investigation  ................................ ................................ .................  24 
4.2.1 Primary  Efficacy  Hypothesis  ................................ ................................ ...........................  24 
4.3 Label Claims to be Assessed in the  Clinical  Investigation  ................................ .....................  24 
5 Study  Design  ................................ ................................ ................................ .........  24 
5.1 General Description of the Clinical Investigation (ICH  E3; 9) ................................ .................  24 
5.1.1 Study Endpoints (ICH  E9; 2.2.2)  ................................ ................................ .....................  [ADDRESS_769163] Equipment, Maintenance,  and Calibration  ................................ ..............................  25 
5.2 Exposure to VR101 and the  Sham Ring  ................................ ................................ ................  25 
5.3 Study  Participants  ................................ ................................ ................................ .................  25 
5.3.1 Inclusion Criteria for Participant Selection (ICH E3; 9.3 ICH  E9; 2.2.1)  ..........................  25 
5.3.2 Exclusion criteria for  participant  selection  ................................ ................................ ....... 26 
5.3.3 Points  of Enrollment  ................................ ................................ ................................ ........  27 
5.3.4 Duration  of Participation  ................................ ................................ ................................ .. 27 
5.3.5 Randomization  and Blinding  ................................ ................................ ...........................  27 
5.3.6 Participant Withdrawal  / Discontinuation  ................................ ................................ .........  28 
5.3.7 Number  of Participants  ................................ ................................ ................................ ... 29 
5.3.8 Estimated Time Needed to  Enroll  Participants  ................................ ................................  29 
5.3.9 Total  Study  Duration  ................................ ................................ ................................ ....... 29 
5.3.10  Procedures for the Replacement  of Participants  ................................ .............................  29 
5.4 Procedures  ................................ ................................ ................................ ............................  29 
5.4.1 Participant  Screening  ................................ ................................ ................................ ...... 29 
5.4.2 Participant Enrollment  / Recruitment  ................................ ................................ ...............  29 
5.4.3 Visit Schedule and Description: Frequency and Timing of Study Variables (ICH E3;  
9.5.1. ICH  E9; 2.2.2)  ................................ ................................ ................................ ....................  30 
5.4.4 Interim Follow -Up Call Schedule  ................................ ................................ .....................  34 
5.4.5 Terminal  Follow -Up Procedure  ................................ ................................ .......................  34 
5.4.6 FSFI (Female Sexual Function  Index)  Survey  ................................ ................................  34 
5.4.7 Intercourse / Lubricant  Use Survey  ................................ ................................ .................  35 
  
J3 Bioscience, 
Inc. Clinical Investigation Plan and Protocol CI03  
CI03 -CIP 
Rev. 0 2 
Page 1 of 60 A Clinical Investigation to Evaluate Efficacy of the J3  
Bioscience Lubricating Intravaginal Ring, VR101, as a 
Personal Lubricant Device in Women  
 During Day 7, 14 and 21 Phone Calls and Visit 2, participants will be given a survey to assess:  35 
5.4.8  Ring Use Log  ................................ ................................ ................................ ..................  35 
5.4.9  Factors That May Influence the Outcome of  the Investigation  ................................ ........  35 
5.5 Monitoring  Plan ................................ ................................ ................................ .....................  35 
5.6 Labeling  ................................ ................................ ................................ ................................ . 36 
6 Justification For The  Clinical  Investigation  ................................ ........................  37 
6.1 Need for the Proposed  Clinical  Investigation  ................................ ................................ .........  37 
6.2 Safety of VR101 in  Prior  Studies  ................................ ................................ ...........................  37 
6.3 Justification of  Study  Endpoints  ................................ ................................ .............................  37 
6.3.1 FSFI -LD ................................ ................................ ................................ ..........................  37 
6.3.2 Adverse Events / Adverse  Device Effects  ................................ ................................ ....... [ADDRESS_769164]  Assessment  (CHA)  ................................ ................................ .......................  38 
7.3 Risk-Benefit  Ratio  ................................ ................................ ................................ ..................  38 
8 Statistical  considerations ................................ ................................ .....................  38 
8.1 Statistical  Hypotheses  ................................ ................................ ................................ ...........  38 
8.1.1 Primary  Efficacy  ................................ ................................ ................................ ..............  38 
8.1.2 Exploratory  ................................ ................................ ................................ ......................  39 
8.2 Analysis  Groups  ................................ ................................ ................................ ....................  39 
8.2.1 Target  population  ................................ ................................ ................................ ............  39 
8.2.2 Full Analysis  Set (ITT)  ................................ ................................ ................................ ..... 39 
8.2.3 Modified  ITT ................................ ................................ ................................ ....................  39 
8.2.4 Complete  Case  Set ................................ ................................ ................................ .........  39 
8.2.5 Per Protocol  Analysis  ................................ ................................ ................................ ...... 39 
8.3 Sample Size Determination (ICH E3; 9.7.2 ICH  E9; 3.5) ................................ .......................  40 
8.4 Expected  Drop -Out Rates  ................................ ................................ ................................ ..... 41 
8.5 Pass / Fail Criteria of the  Clinical  Investigation  ................................ ................................ ...... 42 
8.6 Adjustment  for Multiplicity  ................................ ................................ ................................ ...... 42 
8.7 Disposition of Missing  Data (ICH E3; 9.7.1, [IP_ADDRESS] ICH E9; 5.3. EMA Guideline on Missing  
Data in Confirmatory Clinical Trials, ICH E9  (R1) addendum)  ................................ .........................  [ADDRESS_769165]  Disposition  Determination  ................................ ................  44 
9 Data Collection  and Management  ................................ ................................ ........  44 
10 Amendments to  the CIP................................ ................................ ........................  45 
11 Deviations from  the CIP ................................ ................................ ........................  45 
11.1 Acceptable Circumstances for Deviations to  the CIP ................................ ............................  45 
11.2 Procedure for Disqualification and Replacement of a  Principal  Investigator  ..........................  45 
12 Device  Accountability  ................................ ................................ ...........................  45 
12.1 Access  to Devices  ................................ ................................ ................................ .................  45 
12.2 Physical Location of  Investigational  Devices  ................................ ................................ .........  46 
12.3 Use of  Devices  ................................ ................................ ................................ ......................  46 
12.4 Distribution of Devices from the Sponsor to  Clinical  Sites  ................................ .....................  46 
12.5 Device  Accountability  Log ................................ ................................ ................................ ..... 46 
13 Adverse Events, adverse device effects and device deficiencies and reporting events and  
deficiencies  ................................ ................................ ................................ ..................  46 
13.1 Definitions  ................................ ................................ ................................ .............................  47 
13.2 Anticipated Adverse  Events  (AE) ................................ ................................ ..........................  48 
13.3 Anticipated Adverse Device  Effects  (ADE)  ................................ ................................ ............  [ADDRESS_769166]  (IRB)  ................................ ................................ ............................  54 
14.2 Responsibilities  ................................ ................................ ................................ .....................  54 
14.2.1  Principal  Investigator  ................................ ................................ ................................ ...... 54 
14.2.2  A Sub -Investigator (Sub -I, e.g., Medical  Professional, Associates)  ................................  54 
14.2.3  Sponsor  ................................ ................................ ................................ ..........................  55 
14.2.4  Monitor  ................................ ................................ ................................ ............................  55 
15 Vulnerable Populations  ................................ ................................ ........................  55 
16 Suspension or premature termination of the clinical investigation  (Stoppi[INVESTIGATOR_14123])  [ADDRESS_769167]  ................................ ................................ ..............................  56 
18 Publication  policy  ................................ ................................ ................................ . 56 
19 Records and Reports  ................................ ................................ ............................  57 
20 Bibliography  ................................ ................................ ................................ ..........  57 
 
Appendix A: FSFI Survey and Scoring Method  
 
Appendix B: VR101 Investigational Labeling / Instructions for Use 
Appendix C: VR101 Clinical Hazard Assessment  
Investigational Sites/PIs: Advanced Clinical Research/aka Velocity Clinical Research  
 
Site 01 – West Jordan, Utah:  
Principal Investigator: 
(Study Doctor)  Barbara Rizzardi, MD  
Telephone:  [PHONE_12112] (24 Hours)  
Address:  Advanced Clinical Research 
[ADDRESS_769168] Jordan, UT [ZIP_CODE]  
 
Site 02 – Meridian, Idaho  
Principal Investigator: 
(Study Doctor)  Mark Turner, MD  
Telephone:  [PHONE_12113] (24 Hours)  
 
 
J3 Bioscience, 
Inc. Clinical Investigation Plan and Protocol CI03  
CI03 -CIP 
Rev.  02 
Page 2 of 60 A Clinical Investigation to Evaluate Efficacy of the J3  
Bioscience Lubricating Intravaginal Ring, VR101, as a 
Personal Lubricant Device in Women  
  
Address:  Advanced Clinical Research 
[ADDRESS_769169] (IRB) : 
IntegReview IRB  
3815 S. Capi[INVESTIGATOR_585032] 230  
Austin, [LOCATION_007] [ZIP_CODE]  
[PHONE_12114]  
 
 
STUDY SUMMARY  
 
Title A Clinical Investigation to Evaluate Efficacy of the J3 
Bioscience Lubricating Intravaginal Ring VR101 as a 
Personal Lubricant Device in Women  
Short Title  Efficacy of VR101 as a Personal Lubricant  
Protocol Number  CI03 -CIP 
Phase  Pi[INVESTIGATOR_585033], double -blind, sham -controlled, 4 -week parallel group 
study  
Study Duration  7 weeks (including a 2 -week open -label extension and a 1 -week safety 
follow -up) 
Study Centers  Study is designed as a multi -center trial (at least 2 sites) with 
approximately equal enrollment  
Objectives  Primary  
To evaluate the efficacy of VR101 as a personal lubricant for vaginal 
application, intended to moisturize and lubricate, to enhance the ease 
and comfort of intimate sexual activity and supplement the body’s 
natural lubrication (as shown by [CONTACT_585058] -LD ≥ 4.5 following 4 consecutive weeks of weekly ring use being 
higher for VR101 than the sham).  
Number of 
Participants  A minimum of 160 females (80 in each arm) will be randomized to 
VR101 or sham ring during the treatment phase of the study  
 
 
J3 Bioscience, 
Inc. Clinical Investigation Plan and Protocol CI03  
CI03 -CIP 
Rev. 0 2 
Page 1 of 60 A Clinical Investigation to Evaluate Efficacy of the J3  
Bioscience Lubricating Intravaginal Ring, VR101, as a 
Personal Lubricant Device in Women  
  
Diagnosis and Main 
Inclusion Criteria  Sexually active women who report with individual question scores of 
between 1 and 3, inclusive, on all FSFI Lubrication Domain questions  
(7, 8, 9, and 10).  
Study Product, 
Route, Regimen  VR101 is a personal lubrication device, for vaginal application, 
intended to moisturize and lubricate, to enhance the ease and 
comfort of intimate sexual activity, and supplement the body's 
natural lubrication.  
 
Participants will be instructed to exchange with a new device 
every 7 ± 1 days.  
Duration of 
administration  6 weeks (4 -week double -blind parallel group study plus 2-week open 
label extension)  
Reference Therapy  VR101 will be compared to a sham ring  
Statistical 
Methodology  The primary efficacy analysis will be a superiority comparison between 
the proportion of participants who report FSFI -LD (lubrication domain 
score) scores of 4.5 or greater after using VR101 or the sham ring for 4 
weeks.  
J3 Bioscience, Inc.  CONFIDENTIAL   
  
J3 Bioscience, 
Inc. Clinical Investigation Plan and Protocol CI03  
CI03 -CIP 
Rev. 0 2 
Page 12 of 60 A Clinical Investigation to Evaluate Efficacy of the J3  
Bioscience Lubricating Intravaginal Ring VR101 as a 
Personal Lubricant Device in Women  
  
1 SYNOPSIS  
This Clinical Investigation (CI03) is designed to validate the efficacy of the VR101 
lubricating Intravaginal Ring (IVR) as a personal lubricant device. In the proposed clinical 
investigation, participants will be divided into two groups for the study, VR101 device 
and sham ring. Participants will use VR101 devices or sham rings for [ADDRESS_769170] 160 subjects (80 in each group) are 
randomized to the VR101 device or sham ring group.  
 
As this is a multi -site study, the study coordinator will monitor enrollment to ensure 
nominally equ al representation of the [ADDRESS_769171] ~1/3 of the participants (54) will be enrolled at each site.  
 
1.2 Investigational  Devices  
VR101 devices and sham rings for the clinical investigation will b e manufactured by [CONTACT_585059] [ZIP_CODE] -certified and/or FDA Quality System Regulation (QSR) -compliant vendor.  
 
1.3 Summary of Endpoints (see Section 5.1.1 for  details)  
1.3.1 Primary Efficacy  Endpoint  
• Proportion of participants that experience increased vaginal lubrication that 
enhances ease and comfort of intimate sexual activity, defined as a FSFI -LD ≥ 
4.5 following 4 consecutive weeks of weekly ring use.  
 
1.3.2 Safety Endpoint  
• All adverse events (AE) and adverse device events (ADEs) will be recorded  throughout 
the s tudy and will be assessed for severity and their relatedness to VR101  use. 
1.3.3 Exploratory  Endpoints  
• Improvement in FSFI total  score  
• Improvement in all FSFI domains (except lubrication), which include desire, 
arousal, orgasm, satisfaction, and pain  domains  
J3 Bioscience, Inc.  CONFIDENTIAL   
  
J3 Bioscience, 
Inc. Clinical Investigation Plan and Protocol CI03  
CI03 -CIP 
Rev. 0 2 
Page 13 of 60 A Clinical Investigation to Evaluate Efficacy of the J3  
Bioscience Lubricating Intravaginal Ring VR101 as a 
Personal Lubricant Device in Women  
  
1.4 Summary of Study Schedule and Study  Schematic  
 
 
 
 
Figure 1. Study Schematic  
 
• After a participant has read and signed the Informed Consent Document and has 
met all inclusion and exclusion criteria, she will be randomized into either the 
VR101 device or sham r ing group.  
• Participants will be instructed to use the randomly assigned device continuously 
and exchange with a new device every 7 days for the next 4  weeks.  
• Study staff will complete a follow -up call with participants on the 7th, 14th, and 21st 
day following randomization to remind them to remove their current device and 
insert a new  ring. 
• Participants will return for a final study visit on day 28 ± 2 where the FSFI survey 
will be  administered.  
• Participants will be offered two additional VR101 device s for a 2 -week open -label 
extension.  
• A final follow -up call will occur 1 week after the end of the open -label  extension.  
 
2 BACKGROUND  
2.1 Purpose  
The purpose of this Clinical Investigation, internally designated CI03, is to evaluate efficacy of 
the J3 Bioscienc e, Inc. (J3 Bio) lubricating intravaginal ring, VR101, as a personal lubricant 
device in women. After reviewing results obtained in CI01, “VR101: A Pi[INVESTIGATOR_585034] a Lubricating Intravaginal Ring to Relieve  the 
Symptoms of Vaginal Dryness,” and in CI02, “A Pi[INVESTIGATOR_585035] -in 
and   
Reminders  
4-Week FSFI 
(N = ~150)  
2-week 
open -label 
extension 
of VR101  
devices  
 
Baseline FSFI 
Randomization 
Initiation/Training 
on Ring Use  
(N = ~160)  
Visit 1 (Day 0)  
 
4-Week 
Treatment Phase  
 Visit 2 (Day 28 + 2) 
Stop Open -Label 
(Day 42 + 2). Final 
Phone Call /  Check -In 
(Day 49 + 2) 
J3 Bioscience, Inc.  CONFIDENTIAL   
  
J3 Bioscience, 
Inc. Clinical Investigation Plan and Protocol CI03  
CI03 -CIP 
Rev. 0 2 
Page 14 of 60 A Clinical Investigation to Evaluate Efficacy of the J3  
Bioscience Lubricating Intravaginal Ring VR101 as a 
Personal Lubricant Device in Women  
  
Safety and Efficacy of J3 Bio Lubricating Intravaginal Ring (VR101) in Relieving Symptoms of 
Vaginal Dryness,” FDA and J3 Bio agreed that VR101  safety had been successfully 
demonstrated.  
 
CI03 is designed to further evaluate VR101 efficacy and will enable continued monitoring of 
VR101 safety. The combined safety and efficacy data from CI01, CI02, and CI03 will be used to 
support a premarket 510(k) notification to the FDA to enable regulatory clearance of the device 
in the [LOCATION_002] (US). The investigation is designed to comply with the requirements of ISO 
[ZIP_CODE], allowing the investigation to also support regulatory submissions a nd registrations in 
other countries.  
 
2.2 Scope  
This procedure applies to the clinical investigation of VR101, Lubricating Intravaginal Ring 
manufactured by J3 Bio, to establish the efficacy of VR101 as a personal lubricant device and 
its substantially equival ent safety and efficacy to the predicate device, Replens® Long -lasting 
Vaginal Moisturizer in Pre -filled Applicators (Replens). Results may be applicable to other 
versions of J3 Bio device designs. Justification for applicability of results to other design s will be 
documented in the Design History File and/or Technical File, as appropriate.  
 
2.3 Summary of VR101 Bench  Testing  
2.3.1 Bench  Tests/Stability  
The following characteristics of VR101 devices have been evaluated and found to be within 
specifications or require d ranges for up to 54 months (real -time equivalent):  
• Visual  appearance  
• Dimensions  
• Mechanical force required to compress  VR101  
• Tensile  strength  
• In vitro release of  glycerol  
 
Condom compatibility also was evaluated and found to be acceptable per ASTM D7661 -10. 
 
2.3.[ADDRESS_769172] articles or VR101 components, as appropriate, were 
acceptable, indicating VR101 and its components wil l not elicit an unacceptable biological or 
toxicological response under anticipated end -use conditions. Additionally, cytotoxicity testing 
sponsored by [CONTACT_585060], Inc. (now Lubrizol Advanced Materials, Cleveland, OH) of the raw 
Tecophilic® HP-60D-35 polym er (also sold as Excipi[INVESTIGATOR_585036]® Polymer PY -PT42DE35) was performed at Toxikon Laboratories (Bedford, MA). The 
extracts of the polymer test article showed no evidence of reactivity in these studies. Thus, the  
J3 Bioscience, Inc.  CONFIDENTIAL   
  
J3 Bioscience, 
Inc. Clinical Investigation Plan and Protocol CI03  
CI03 -CIP 
Rev. [ADDRESS_769173].  
 
Based on the results obtained in the ISO [ZIP_CODE] and FDA -recommended studies, J3 Bio 
concludes that the biological and toxicological risks associated  with the use of VR101 are low 
and acceptable, justifying the continued use of VR101 in a clinical investigation.  
 
2.3.3 Summary of VR101 Preclinical  Testing  
J3 Bio and the University of Utah (Department of Bioengineering) conducted nonclinical in vivo 
efficacy studies in a sheep model to support the development of and establish feasibility of 
VR101 use in providing vaginal moisturization and lubrication. The m odel was selected because 
there are similarities between human and sheep vaginal size and shape. Studies were 
performed to assess the release of the lubricant solution and the ability of VR101 to moisturize 
and lubricate the sheep vaginal tract. Vaginal fl uid was collected for up to [ADDRESS_769174] 
techniques during insertion of either VR101 or “placebo” (empty reservoir, non -glycerol - 
releasing) hydrophilic polyurethane (HPU) sham ring to assess potential effectiveness. Over the 
7-day study period, s heep treated with VR101 exhibited a statistically significant increase in 
available vaginal fluid versus placebo -treated and baseline control subjects. Collected fluid 
volumes were 4.[ADDRESS_769175] been perfor med on VR101 to -date and are summarized in 
Table 1 and Sections 2.4.1 and 2.4.2.  
 
TABLE 1 SUMMARY OF COMPLETED VR101 CLINICAL TRIALS  
 
 
Study   
 
Subjects 
Enrolled   
 
Design   
 
Regimen   
 
Objective(s)   
 
Diagnosis /  
Key Eligibility Criteria   
 
Primary 
Endpoints/Outcomes  
 
CI01 - Pi[INVESTIGATOR_2268]  
21  
Open -Label   
VR101, 2 devices 
used consecutively 
for 7 days each (14 
days total)   
Obtain preliminary data on the 
ability of the VR101 to relieve 
the symptoms of vaginal 
dryness in post - and 
perimenopausal women.   
Women over the age of [ADDRESS_769176] - 
menopausal women with 
self-reported vaginal 
dryness   
Statistical improvement in 
modified VHI (without pH) on 
day 3 and day 14  
90% reduction in vaginal 
dryness frequency after 2 
weeks of use  
No serious adverse events 
in study population  
J3 Bioscience, Inc.  CONFIDENTIAL   
  
J3 Bioscience, 
Inc. Clinical Investigation Plan and Protocol CI03  
CI03 -CIP 
Rev. 0 2 
Page 16 of 60 A Clinical Investigation to Evaluate Efficacy of the J3  
Bioscience Lubricating Intravaginal Ring VR101 as a 
Personal Lubricant Device in Women  
  
 
 
Study   
 
Subjects 
Enrolled   
 
Design   
 
Regimen   
 
Objective(s)   
 
Diagnosis /  
Key Eligibility Criteria   
 
Primary 
Endpoints/Outcomes  
 
CI02 – 
Efficacy   
72  
Randomized, 
Double -Blind 
Crossover, 
Sham - 
Controlled   
VR101 and sham 
ring, 4 devices 
used consecutively 
for 7 days each (28 
days total)   
To demonstrate the efficacy  of 
VR101 in treating the 
symptoms of vaginal  dryness  
To validate potential labeling 
claims regarding VR101  use: 
VR101 relieves the symptoms 
of vaginal dryness for up to [ADDRESS_769177] 60 days; and 
whose clinician -assigned 
baseline Vaginal Health 
Index (VHI) score was 22 
or lower.   
Primary efficacy endpoint 
(superior VHI improvement 
vs sham after 28 days of 
use) not me t, but efficacy 
suggested through post -hoc 
analyses  
    VR101 is comfortable during 
use.   
    To demonstrate that VR101 
may be used by [CONTACT_585061],  justifying  
its over -the-counter (OTC)  use.   
    To further the 
scientific/technical 
understanding of VR101 by 
[CONTACT_585062]’s experiences    
 
CI02 – Long - 
Term Safety   
57  
Open -Label   
VR101, 13  
devices* used 
consecutively, each 
for 7 days (91 days  
total)   
To assess the safety of VR101 
when used to treat the 
symptoms of vaginal dryness.    
No serious adverse events 
in 890 VR101 insertions  
 
*Total, in one study group this included the [ADDRESS_769178]-in-human pi[INVESTIGATOR_585037] (CI01) in [ADDRESS_769179] -menopausal women to assess preliminary safety and feasibility of use 
of VR101 in relieving the symptoms of vaginal dryness. In the study, participants were instructed 
to use  two VR101 devices consecutively, each for 7 consecutive days, for a total of 14 
continuous days of VR101 use.  
J3 Bioscience, Inc.  CONFIDENTIAL   
  
J3 Bioscience, 
Inc. Clinical Investigation Plan and Protocol CI03  
CI03 -CIP 
Rev. 0 2 
Page 17 of 60 A Clinical Investigation to Evaluate Efficacy of the J3  
Bioscience Lubricating Intravaginal Ring VR101 as a 
Personal Lubricant Device in Women  
  
Encouraging results were achieved when assessing relief of vaginal dryness objectively using a 
modified composite Vaginal Health I ndex (VHI) score, which equally weighted clinical 
assessments of vaginal elasticity, fluid volume, epi[INVESTIGATOR_585038]. Across the 
study population, mean composite modified VHI scores increased versus baseline values 
collected before device i nsertion during Visit 1 at each subsequent visit, with statistically 
significant increases ( p ≤ 0.05, one -tailed, normally approximated Wilcoxon signed -rank test) 
observed [ADDRESS_769180] 7 
days of ring use, 0.4 days during the second 7 days of ring use (all p < 0.005, one -tailed, 
normally approximated Wilcoxon signed -rank test).  
 
Regarding safety, no serious safety concerns or adverse events were noted or reported by [CONTACT_585063]. Moreover, all 21 participants that enrolled successfully 
completed the study, including follow -up. 
 
2.4.2  Summary of VR101 Pi[INVESTIGATOR_585039]  (CI02)  
CI02 was designed to evaluate the safety and efficacy of VR101 and establish its  substantial 
equivalence to the predicate device, Replens® Long -lasting Vaginal Moisturizer in Pre -filled 
Applicators (Replens). In total, [ADDRESS_769181] 60 days that i nterfered with daily activities.  
 
Participants were randomized upon enrollment to one of two crossover groups and were 
instructed to use either four each VR101 lubricating devices or four each sham rings 
consecutively, each for 7 days and a total of 28 days. After a 3 -week washout period, 
participants then crossed over to use of their respective alternate device (sham ring or VR101 
device) and were again instructed to use four rings or devices consecutively for 7 days each (28 
days total use). Participan ts were then asked to continue use of VR101 for at least [ADDRESS_769182] were asked to continue VR101 
use for an additio nal 9 weeks (13 weeks total), while participants who finished using the sham 
ring last were switched back to VR101 use for 13 additional weeks (17 weeks total, 13 of them 
consecutive).  
 
Of [ADDRESS_769183] any been recorded with use of VR101 to date.  
 
Efficacy primarily was assessed using the composite Vaginal Health Index (VHI), previously 
published by [CONTACT_585064]. (1991 and 1992). During the double -blind crossover portion of  
J3 Bioscience, Inc.  CONFIDENTIAL   
  
J3 Bioscience, 
Inc. Clinical Investigation Plan and Protocol CI03  
CI03 -CIP 
Rev. 0 2 
Page 18 of 60 A Clinical Investigation to Evaluate Efficacy of the J3  
Bioscience Lubricating Intravaginal Ring VR101 as a 
Personal Lubricant Device in Women  
  
CI02, VR101 improved composite Vaginal Health Index scores, when used for 28 days over  
baseline scores (Change in VHI (ΔVHI) = +1.76 ± 3.32, p < 0.0001, paired t-test vs baseline, N  
= 66). However, missing data in CI02 greatly contributed t o a failure to meet the primary efficacy 
endpoint under the original statistical analysis plan.  
 
In [ADDRESS_769184] between use of VR101 and the sham ring (0.01 ≤ p ≤ 0.02).  
 
The following patient -reported endpoints were also assessed to provide additional assessments 
of efficacy and usability and to substantiate labeling claims:  
• Participants reported a significantly lower vaginal dryness severity during the final [ADDRESS_769185] VR101 use when compared to the 7 days prior to ring use ( p < 0.0001, 
paired t-test).  
• Ninety -three percent (93%) of participants reported t hat VR101 was easy to use by 
[CONTACT_585065]101  device.  
• When queried in daily diaries if VR101 was comfortable during use,  participants 
responded favorably 88% of the  time.  
 
3 IDENTIFICATION AND DESCRIPTION OF THE INVESTIGATIONAL 
DEVICE  
3.1 Summary Description of  VR101  
VR101 is a clear, flexible, torus -shaped lubricating intravaginal ring (IVR); see Figure 2, Device 
Image, and Figure 3, VR101 Schematic Drawing). VR101 is manufactured from hollow tubin g 
formed from Excipi[INVESTIGATOR_585040]® Polymer PY -PT42DE35 
(identical to Tecophilic® HP-60D-35, Lubrizol Advanced Materials, Cleveland, OH) by [CONTACT_585066] -melt 
extrusion.  
J3 Bioscience, Inc.  CONFIDENTIAL   
  
J3 Bioscience, 
Inc. Clinical Investigation Plan and Protocol CI03  
CI03 -CIP 
Rev. [ADDRESS_769186]® Polymer PY -PT42DE35 (formerly Tecophilic HP -60D- 
35) and cutting the extruded tubin g into short segments that are the length of the 
eventual circumference of the finished VR101 devices. The tubing segments are filled 
with a solution of 87/10/3 (wt %) USP grade glycerol/USP grade water/USP grade 
sodium chloride solution. The ends of the t ubing are subsequently thermally fused to 
form a continuous ring. The filled ring is placed into a mold and briefly heated in an 
annealing step to release stresses and form the ring into its final circular shape. The 
rings are packaged in foil -backed polye thylene pouches containing 0.25 mL of a 
glycerol/water solution.  
 
Device dimensions are comparable to commercially available IVRs. Table 2 lists the 
dimensions of VR101.  

J3 Bioscience, Inc.  CONFIDENTIAL   
  
J3 Bioscience, 
Inc. Clinical Investigation Plan and Protocol CI03  
CI03 -CIP 
Rev. 0 2 
Page 21 of 60 A Clinical Investigation to Evaluate Efficacy of the J3  
Bioscience Lubricating Intravaginal Ring VR101 as a 
Personal Lubricant Device in Women  
  
Table 2. Nominal Dimensions of VR101  
Ring Characteristic  Dimension  
Outer Diameter (ring)  55 mm  
Cross -Sectional Diameter (tubing)  5.50 mm  
Wall thickness (tubing)  0.65 mm  
 
Table 3 identifies composition and weight of VR101.  
 
Table 3: Nominal Composition and Weight of VR101  
Device Component  Weight  
Tubing (Pathway® PY-PT42DE35)  2.0 g  
Lubricant Solution (Liquid Core)  2.5 g (total)  
Glycerol, USP  2.2 g  
Water, USP  0.2 g  
Sodium Chloride, USP  0.1 g  
Total Mass  4.5 g  
 
Table 4 provides the specifications for VR101 constituents. VR101 does not contain any 
drugs or active pharmaceutical ingredients (APIs).  
 
Table 4. Detailed Specifications for VR101 Constituents  
Ring  
Component  Material Description  
Tubing  Hydrophilic aliphatic polyether urethane (HPU) tubing,  
extruded from Lubrizol medical grade Pathway™ PY - 
PT42DE35  
Lubricant Solution (present in the Lumen of VR101, also referred to as 
“Liquid Core”)  
Glycerol  Glycerol, Synthetic  
Chemical Abstract Services: CAS #: 56 -81-5 
Molecular Formula: C 3H8O3 
Meets relevant standards listed in:  
• EP: European  Pharmacopeia  
• USP: [LOCATION_002]  Pharmacopeia  
• BP: British  Pharmacopeia  
• JP: Japanese  Pharmacopoeia  
Certified free from Bovine and Transmissible Spongiform 
Encephalopathy  
Water  Water, Deionized 
CAS # 7732 -18-5 
Molecular Formula: H 2O 
Meets relevant standards listed in:  
• EP: European  Pharmacopeia  
• USP: [LOCATION_002]  Pharmacopeia  
• JP: Japanese  Pharmacopoeia  
J3 Bioscience, Inc.  CONFIDENTIAL   
  
J3 Bioscience, 
Inc. Clinical Investigation Plan and Protocol CI03  
CI03 -CIP 
Rev. 0 2 
Page 22 of 60 A Clinical Investigation to Evaluate Efficacy of the J3  
Bioscience Lubricating Intravaginal Ring VR101 as a 
Personal Lubricant Device in Women  
  
Table 4. Detailed Specifications for VR101 Constituents  
Sodium 
Chloride  Sodium Chloride 
CAS # 7647 -14-5 
Molecular Formula: NaCl  
Meets relevant standards identified in:  
• EP: European  Pharmacopeia  
• USP: [LOCATION_002]  Pharmacopeia  
 
3.2 Principles of Operation of  VR101  
Upon insertion, the glycerol solution in the VR101 device begins to pass through the 
semipermeable polyurethane ring wall into the vagina where it provides lubrication and 
moisture. The release of the glycerol solution is prolonged as its transport into the vagina 
is modulated by [CONTACT_585067]. 
 
3.3 VR101 Intended  Use 
VR101 is a personal lubrication device, for vaginal application, intended to moisturize 
and lubricate, to enhance the ease and comfort of intimate sexual activity, and 
supplement the body's natural lubrication.  
 
3.4 Lubricating  Agent  
Glycerol is a lubricat ing agent, generally recognized as safe (GRAS) by [CONTACT_1622], with a 
long history of safe clinical use in vaginal applications. The intended duration of vaginal 
lubrication (7 consecutive days) provided by [CONTACT_585068]101 device is based on the results 
of preclini cal evaluations in sheep and two clinical investigations in women. See 
Sections 2.3.3 and 2.4 above for summaries of the preclinical and pi[INVESTIGATOR_585041], 
respectively.  
 
3.5 Supplier of VR101 Devices and Sham  Rings  
VR101 devices and sham rings manufactured by [CONTACT_63815] [ZIP_CODE] -certified and/or FDA 
Quality System Regulation (QSR) -compliant vendor and will supply the products for the 
clinical investigation.  
 
3.6 VR101  Identification  
The individual packages containing each investigational device or sham rin g will be 
labeled with the device name ("VR101 Lubricating Intravaginal Ring") and expi[INVESTIGATOR_69089]. They also will be labeled with the statement “for investigational use only” (see 
Section 5.6, below).  
J3 Bioscience, Inc.  CONFIDENTIAL   
  
J3 Bioscience, 
Inc. Clinical Investigation Plan and Protocol CI03  
CI03 -CIP 
Rev. [ADDRESS_769187] for up to 7 consecutive days. After 7 days, the ring is removed by [CONTACT_277695], discarded , and, at the user’s discretion, replaced with a fresh VR101 ring.  
 
VR101 is intended to be available as an over -the-counter (OTC) product that will not 
require healthcare professional assistance or supervision for use. The user will not be 
assisted with use of the device. As such, the user must be able to insert and remove the 
device solely based on reading the provided instructions for use (IFU) and labeling. All 
applicable warnings, precautions and contraindications are listed on the IFU.  
 
3.9 Sham  Rings  
To demonstrate that efficacy results from this study are clinically meaningful, 
lubricating/moisturizing effects not directly resulting from VR101 must be adequately 
controlled. Therefore, performance of VR101 will be compared that of a sham ri ng. 
 
Sham rings will be manufactured identically to VR101, except:  
 
• Tubing will be manufactured with Biomerics Quadraflex ALE -91A, an inert (non - 
hydrophilic) aliphatic polyether urethane. ALE -91A has identical manufacturer - 
reported flexural modulus (per ASTM D790) to Tecophilic HP -60D-35 (Pathway 
PY-PT42DE45), is non -hemolytic (per ASTM D756), is non -cytotoxic (per ISO 
[ZIP_CODE] -5), and has been used to manufacture FDA -approved, long -term (>30 
day) implantable medical  devices.  
• No lubricating solution will be added to the device lumen or the device  package.  
 
4 OBJECTIVES AND HYPOTHESES OF THE CLINICAL 
INVESTIGATION  
4.1 Study Objectives (ECH E3;  8.) 
4.1.1 Primary Objectives of the Clinical  Investigation  
To evaluate the efficacy of VR101 as a personal lubricant for vaginal application, 
intended to increase vaginal lubrication and enhance the ease and comfort of 
intimate sexual activity.  
J3 Bioscience, Inc.  CONFIDENTIAL   
  
J3 Bioscience, 
Inc. Clinical Investigation Plan and Protocol CI03  
CI03 -CIP 
Rev. 0 2 
Page 24 of 60 A Clinical Investigation to Evaluate Efficacy of the J3  
Bioscience Lubricating Intravaginal Ring VR101 as a 
Personal Lubricant Device in Women  
  
4.2 Hypothesis of the Clinical  Investigation  
4.2.1 Primary Efficacy  Hypothesis  
Compared to the sham device, a significantly gre ater proportion of participants who use 
VR101 for 4 consecutive weeks will experience increased vaginal lubrication that 
enhances ease and comfort of intimate sexual activity as assessed by [CONTACT_585069] (FSFI -LD > 4.5). 
 
4.3 Label Claims to be Assessed in the Clinical Investigation 
Successful confirmation of the Primary Efficacy Hypothesis will also validate the following 
proposed VR101 Label  Claims:  
• Use one ring every 7 days to provide lubrication during sexual activity or  intercourse  
• Use one ring every 7 days to reduce discomfort during sexual activity or  intercourse  
• Use one ring every 7 days for increased comfort and  lubrication  
• Helps replenish vaginal lubrication when used once every 7  days  
• Provides vaginal lubrication when used once every 7  days  
5 STUDY  DESIGN  
5.1 General Description of the Clinical Investigation (ICH E3;  9) 
Clinical Phase : Pi[INVESTIGATOR_585042] : At least 160 participants will be randomized (1:1 ratio) into two groups to 
use either VR101 or the sha m ring.  
 
Study Population : Sexually active women who report experiencing lack of lubrication 
during intercourse, give consent to participate and meet all inclusion/exclusion criteria.  
 
Study Type : Multi -center, double -blind, sham -controlled parallel group study (followed by 
[CONTACT_402883] -label extension).  
 
Study Products : VR101 devices and sham rings (see descriptions above)  
 
Study Regimen : Participants will be randomly assigned to receive either VR101 or the 
sham ring. Participants will then use 4 devices consecutively for 7 days each, (28 days 
total). Participants will be allowed to use VR101 for 2 weeks following the double -blind 
study in an open -label extension.  
 
5.1.1 Study Endpoints (ICH E9; 2.2.2)  
• Primary : Proportion of participants that experience increased vaginal lubrication 
that enhances  ease  and comfort  of intimate  sexual  activity,  defined  as an FSFI -LD 
≥ 4.5 with 4 consecutive weeks of weekly ring use.  
J3 Bioscience, Inc.  CONFIDENTIAL   
  
J3 Bioscience, 
Inc. Clinical Investigation Plan and Protocol CI03  
CI03 -CIP 
Rev. 0 2 
Page 25 of 60 A Clinical Investigation to Evaluate Efficacy of the J3  
Bioscience Lubricating Intravaginal Ring VR101 as a 
Personal Lubricant Device in Women  
  
• Exploratory : Improvement in the Female Sexual Function Index (FSFI) total composite 
score (Rosen 2000) and its domains (Desire, Arousal, Lubrication, Orgasm, Satisfaction 
and Pain) during 28 days of  use. 
 
• Safety endpoints  monitored : 
o Any adverse events and adverse device effects  (ADE)  
5.1.2 Measures to Minimize  Bias  
• Participants will not have access to their previous responses, and thus, in any 
given FSFI survey participants will be unable to directly reference their previous 
responses.  
• All participants, regardless of randomization status, will be presented with the 
same study materials, including device packaging and labeling, will undergo the 
same measurements, and will be presented with the same survey  questions.  
5.1.[ADDRESS_769188] equipment is needed for evaluation of safety or efficacy of device use.  
 
5.2 Exposure to VR101 and the Sham  Ring  
Participants will use VR101 for up to 42 (±2) days or the sham ring for up to 28 (±2) 
days.  
 
5.3 Study  Participants  
5.3.1 Inclusion Criteria for Participant Selection (ICH E3; 9.3 ICH E9; 
2.2.1)  
 
Clinical Investigation Participants Must:  
1. Completely understand and sign the informed consent form (ability to read and 
understand the consent form in the English  language).  
2. Be at least 21 years of  age. 
3. Express willingness to comply with the entire study visit schedule (see Table 7 in 
study procedures  section).  
4. Over the course of the  study:  
a. Abstain from the use of any vaginal moisturizers or lubricants or any other 
topi[INVESTIGATOR_585043]  
b. Abstain from using lubricated or spermicide -containing male or female 
condoms  
c. Abstain from vaginal intercourse with a male partner using a lubricated 
condom  
J3 Bioscience, Inc.  CONFIDENTIAL   
  
J3 Bioscience, 
Inc. Clinical Investigation Plan and Protocol CI03  
CI03 -CIP 
Rev. [ADDRESS_769189] not initiate, modify or discontinue a regimen of HRT (hormone 
replacement therapy) or estrogen -containing birth  control.  
 
NOTE : women who have been using non -vaginal HRT or estrogen - 
containing birth control (e.g., oral, transdermal) on a regular dosing 
interval continuously for at least 3 months may continue on the same 
regimen during the study  
 
f. Abstain from use of any other vaginally -placed devices (e.g. ring, 
diaphragm, cervical cap, pessary  products)  
g. If able to get pregnant, use an approved method of contraception (per 
remainder of I/E criteria) to reduce their risk of becoming pregnant during 
the study.  
 
5. In the previous [ADDRESS_769190] had or attempted sexual intercourse with a male 
partner a minimum of twice per mon th (on  average).  
6. Respond to all 4 individual FSFI Lubrication Questions (7 - 10) with a score of 1, 
2, or 3. 
7. Attempt sexual intercourse at least 4 times during the 4 -week double -blind  study.  
 
5.3.2 Exclusion criteria for participant  selection  
Participants self -reporting any of the following will be ineligible for study entry:  
1. Current use of HRT (Hormone Replacement Therapy) or any  estrogen -containing 
birth control products, unless not applied vaginally and the participant has been 
on a regular dosing interval for at least 3 months prior and is willing to continue 
the same regimen without modification throughout study  participation.  
2. Vulvar or vaginal procedures (biopsies, radiation) in the last 3  months.  
3. Active vulvar or vaginal infections/lesion s or complaints, as well as  undiagnosed 
abnormal genital  bleeding.  
4. History of chronic pelvic pain, interstitial cystitis, vulvar vestibulitis, pelvic 
inflammatory disease within the past [ADDRESS_769191], symptomatic congestive heart failure,  unstable 
angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that 
would limit compliance with study  requirements.  
16. Any condition that in the opi[INVESTIGATOR_585044].  
17. Current use of a vaginally -placed device (e.g. ring, pessary, cervical cap or 
diaphragm) unless willingness to discontinue for the study duration is  expressed.  
18. Pregnancy or plans to become pregnant in the next 6  months.  
19. Current  breastfeeding.  
20. Participation  in a previous ViroPan or J3 Bioscience clinical trial for VR101 (i.e. CI01, CI02)  
 
NOTE: IUD (Intrauterine Device) users may be enrolled provided they commit to 
exercising caution when removing VR101, as IUD strings have been n oted to interfere 
with VR101 removal.  
 
NOTE: Participants who have previously undergone anterior and/or posterior vaginal 
repair and have received a vaginal mesh implant may have difficulty placing VR101 but 
are not automatically excluded from the study.  
 
5.3.3 Points of  Enrollment  
Participants will be considered to be enrolled upon providing consent, meeting all 
inclusion/exclusion criteria and signing the Informed Consent Form.  
 
5.3.[ADDRESS_769192] randomly assigned in a 1:1 ratio to receive either VR101 devices 
or sham rings. A randomization schedule (separate for each site) will be prepared for 
treatment group assignment of each subject. The subject’s randomization number will be  
J3 Bioscience, Inc.  CONFIDENTIAL   
  
J3 Bioscience, 
Inc. Clinical Investigation Plan and Protocol CI03  
CI03 -CIP 
Rev. [ADDRESS_769193] identification (ID) number which is 
assigned at the time of informed consent.  
The subject ID number identifies the subject and consists of the site number plus subject 
number for that site. The randomization number identifies the treatment; the 
randomization schedule provides the correspondence between the subject ID number 
and the randomized treatment identification (VR101 or sham).  
 
The trial will be double -blind, meaning the  subject and Investigator/staff will not have 
access to or knowledge of the subject’s treatment assignment. Further, since the 
Sponsor will create and securely maintain the randomization schedules, the Sponsor 
and Sponsor’s representatives will not be made  aware of a given subject’s 
randomization number until the blind is broken. The Sponsor will ensure that the Study 
Monitor does not ever have access to the randomization assignments.  
 
As this is a multi -site study, the study coordinator will monitor enroll ment to ensure 
nominally equal representation of the [ADDRESS_769194] 1/3 of participants (53) would be enrolled at each site.  
Additionally, the Sponsor will create and securely maintain a separate randomization 
schedule for each site to ensure appropriate site representation in the study groups.  
 
5.3.6 Participant Withdrawal /  Discontinuation  
Participants may voluntarily withdraw from the investigation for any reason at any time. 
However, every e ffort will be made to schedule an Early Termination visit and collect 
final outcome measures as well as ascertain the reason for withdrawal.  
 
Participants who withdraw from the study (or are removed by [CONTACT_2413]) due to an 
Adverse Event will be follo wed as described in Section 13.10.  
 
Participants who begin a menstrual period during ring use should discontinue ring use 
and insert a new ring within 24 hours of cessation of menstruation. When a new ring is 
inserted, ring exchange will still occur on sch eduled days (see Section 5.4.3). For 
example: If the new ring is inserted on day 6, 13, or 20, she will not need to change 
again on day 7, 14 or 21 (respectively) because leaving the ring in will still comply with 
the margin of error in the Visit Schedule.  
 
Participants who become pregnant during the study will be instructed to discontinue use 
of study product and will be dropped from the study. Study staff will refer any such 
participants to a clinical facility for follow -up. 
J3 Bioscience, Inc.  CONFIDENTIAL   
  
J3 Bioscience, 
Inc. Clinical Investigation Plan and Protocol CI03  
CI03 -CIP 
Rev. [ADDRESS_769195] 53 (~1/3 of total) participants must be enrolled at each 
study site.  
 
5.3.[ADDRESS_769196] approximately 3 to 4 months.  
 
5.3.10  Procedures for the Replacement of  Participants  
Participants will not be replaced. Data from all randomized participants will be reviewed 
prior to data lock. Analysis groups and methods for dealing with any missing data will be 
assigned prior to unblinding for the primary and  secondary efficacy analyses. Refer to 
the Draft Statistical Analysis Plan (SAP) for further details. The SAP for this study will be 
finalized and approved prior to final data analysis.  
 
5.[ADDRESS_769197] ing to study site procedures.  
 
5.4.2 Participant Enrollment /  Recruitment  
• Interested women will be invited to learn more about this study. If an interested 
possible participant calls the study coordinator, the potential participant may be 
given information over the phone and emailed (or mailed) the informed consent 
form for  review.  
• The study information will be presented to potential participants and explained. 
Study Visit [ADDRESS_769198] persists and the potential participant 
meets basic inclusion/exclusion criteria. Staff may email the informed consent 
form (ICF) to the potential investigation participant for review before her 
scheduled  visit. 
• A signed copy of the informed consent form (ICF) will be provided to the 
participant.  
• The ICF will be stored with the participant’s record or as part of the required 
investigation documentation.  
J3 Bioscience, Inc.  CONFIDENTIAL   
  
J3 Bioscience, 
Inc. Clinical Investigation Plan and Protocol CI03  
CI03 -CIP 
Rev. 0 2 
Page 30 of 60 A Clinical Investigation to Evaluate Efficacy of the J3  
Bioscience Lubricating Intravaginal Ring VR101 as a 
Personal Lubricant Device in Women  
  
5.4.3 Visit Schedule and Description: Frequency and Timing of Study 
Variables (ICH E3; 9.5.1. ICH E9; 2.2.2)  
Participants must return to th e clinic for determination to return unused study product 
and take a final FSFI survey per the schedule shown in Table 7. At that time, all 
participants will be given the opportunity to use active VR101 rings for a 2 -week period.  
J3 Bioscience, Inc.  CONFIDENTIAL   
  
J3 Bioscience, 
Inc. Clinical Investigation Plan and Protocol CI03  
CI03 -CIP 
Rev. 0 2 
Page 31 of 60 A Clinical Investigation to Evaluate Efficacy of the J3  
Bioscience Lubricating Intravaginal Ring VR101 as a 
Personal Lubricant Device in Women  
  
Table 7. Schedule of Events  
  
Baseline   
Treatment   
Discontinuation/ 
Follow -Up 
Visit  1 PC PC PC 2 Early 
Term***  Final PC  
Day (Nominal)  0 7±1 14±1  21±1  28±2  Study 
Withdrawal  49±2 
(35±2)*  
Informed Consent  X       
Assign Subject 
Number  X       
I/E Criteria  X       
Demographics  X       
Height & Weight  X       
Concomitant 
Therapy  X    X X  
Pregnancy Test  X    X X  
Administer Non - 
Lubricated Condoms  
(if needed)   
X       
Brief Medical History  X       
FSFI Survey  X    X X  
Intercourse /  
Lubricant Use 
Survey    
X  
X  
X  
X  
X  
Dispensing of 
Randomized Product  
/ Insertion of 1st Ring 
in Clinic   
X       
Removal of Final 
Randomized Ring / 
Dispensing of Open - 
Label Product  
Insertion of 1st Ring 
in Clinic       
 
X**   
Adverse Events  X X X X X X X 
Ring Use Log  X X X X X X X** 
Ring Change 
Reminder   X X X    
Returned Ring 
Collection      X X  
*If a participant does not elect to participate in the open -label extension, the follow -up will occur on day 
35±2 instead of day 49±2.  
**Only if the participant elects to participate in the open -label extension  
***Only if a participant decides to withdraw participation before reaching Day 26  
J3 Bioscience, Inc.  CONFIDENTIAL   
  
J3 Bioscience, 
Inc. Clinical Investigation Plan and Protocol CI03  
CI03 -CIP 
Rev. 0 2 
Page 32 of 60 A Clinical Investigation to Evaluate Efficacy of the J3  
Bioscience Lubricating Intravaginal Ring VR101 as a 
Personal Lubricant Device in Women  
  
Visit 1 – Study Start / Randomization (Day 0)  
1. Assign a Subject Number to the prospective participant and complete initial 
screening  procedures.  
2. Participants will be administered the FSFI survey (see Section 5.4.6) by a trained 
member of the study staff. Complete this as early as possible in the Visit, e.g., as 
soon as consent is  obtained.  
3. A staff member will conduct a Concomitant Therapy assessment, during which 
they will assess and record if any hormonal therapi[INVESTIGATOR_585045] 3 months (these may or may not disqualify the 
participant from e nrollment, refer to Inclusion / Exclusion Criteria above). During 
this assessment, women still able to get pregnant will be asked about their 
current birth control method. If the method is allowed by [CONTACT_156587] / exclusion 
criteria (see above), they will be  instructed to continue their same method. If no 
birth control is currently used, or their preferred method is to use condoms, they 
will be offered non -lubricated condoms as to allow them to participate in the 
study.  
4. As part of the demographic assessment, participants will be queried as to their 
menopausal status. If a prospective participant is still able to get pregnant, 
she will be asked to provide a urine sample for a pregnancy  test. 
5. If participant meets all inclusion and exclusion criteria, they will b e enrolled  and 
given a numbered package of randomized study product. All packages will be 
identical in appearance and will contain 6 individually packaged study devices 
(either VR101 or sham ring). All packages will contain a unique number, which 
will be r ecorded by [CONTACT_49124].  
6. Enrolled participants will be shown to a private clinic area or restroom to self - 
insert one of the devices from the package. Participants will be asked to insert 
one of these rings per the instructions for use and without clinician input. If a 
participant has difficulty with placement, she can ask for further instruction or 
choose to not place the ring and will be withdrawn from the study (this will be 
recorded on an Early Termination CRF and reported to the Sponsor). If th e ring 
was successfully placed, the participant will be instructed to leave the first ring in 
the vagina for 7  days.  
NOTE: Used rings / packaging are not intended to be collected by [CONTACT_464]. However, 
the site Study Coordinator may consult the Sponsor t o determine if used devices / 
packaging should be collected in case of any unusual patient reports / adverse  events.  
 
7. Study staff will record the date and time that the ring was successfully placed and 
note any assistance needed from study staff (e.g., physical, verbal) so that it can 
be recorded in the Ring Use Log (Section  5.4.8).  
8. Participants will be instructed to exchange with a fresh ring on day 7, day 14 and 
day 21.  
J3 Bioscience, Inc.  CONFIDENTIAL   
  
J3 Bioscience, 
Inc. Clinical Investigation Plan and Protocol CI03  
CI03 -CIP 
Rev. 0 2 
Page 33 of 60 A Clinical Investigation to Evaluate Efficacy of the J3  
Bioscience Lubricating Intravaginal Ring VR101 as a 
Personal Lubricant Device in Women  
  
NOTE: If the ring is expelled (unless on a normal exchange da y), the participant will be 
asked to rinse it using tap water and reinsert unless it is not appropriate to reinsert the 
expelled ring (e.g., lost in toilet, soiled). If participant is unable or unwilling to reinsert the 
expelled ring, or if the ring has be en out for more than 24 hours, she will be asked to 
store it, if possible, in a provided re -sealable bag and bring it to her next clinic visit. If this 
occurs:  
• If expelled After the ring had been inserted for at least 6 days : she will be asked 
to start her  next scheduled ring a day  early.  
• If the ring had only been inserted for 5 days or less : she will be asked to insert a 
new ring, which will be removed on the next scheduled day (e.g., day 7, 14, 21 or 
28). 
Visit 2 – Final visit, Treatment week 4 (Day 28 ± 2) 
1. Participants will be asked to report any Adverse Events (AEs), and whether or 
not they feel the events were related to use of the investigational device. AEs  will 
be recorded on the Adverse Event Form. Refer to Section 13 for further detail on 
classification of AEs and adverse device effects  (ADEs).  
2. If a participant is still able to get pregnant, she will be asked to provide a  urine 
sample for a pregnancy  test. 
3. Participants will be administered the FSFI survey (see Section 5.4.6) by a trained 
member of the study  staff.  
4. A staff member will conduct a Concomitant Therapy assessment, during which 
they will determine the participant used any unapproved medication (e.g.  change 
of dosing frequency of HRT / hormonal birth  control).  
5. Following the FSFI Sur vey, participants will be given the Intercourse / Lubricant 
Use Survey (see Section 5.4.7) to assess frequency of intercourse and assess if 
any unapproved lubrication sources were  used.  
6. Participants will be again queried as necessary to complete the Ring U se Log 
(see Section 5.4.8) up to all events that occur during Visit 2. If the participant 
does not continue in the open -label extension, then all information needed to fully 
complete all fields of her Ring Use Log should be collected during Visit  2. 
7. Partic ipants will be asked to return any unused devices to study  staff.  
8. A member of the study staff will ensure that all study devices are accounted for, 
i.e., that the number of unused devices returned is reconciled with reported ring 
use. 
9. The participant will then be asked if she would like to participate in an open -label 
extension where she can use VR101 for 2 weeks (two devices, 1 week per 
device). Each participant will be instructed to discontinue use her final VR101 
device at day 42 + 2 and told she will re ceive a final follow -up call on day 49 + 2. 
10. If the participant would like to continue, a member of the study staff will provide 
her with two VR101 devices. Participants will be again shown to a private clinic 
area or restroom to remove her device and (if she has elected to continue)  self- 
J3 Bioscience, Inc.  CONFIDENTIAL   
  
J3 Bioscience, 
Inc. Clinical Investigation Plan and Protocol CI03  
CI03 -CIP 
Rev. [ADDRESS_769199] to take t he rings with her and insert later at 
her convenience. The participant should dispose of her used ring in the restroom 
wastebasket, used rings are not intended to be collected by [CONTACT_464].  
Early Termination Visit  
1. If a participant withdraws consent durin g the study (before Day 26, attempt to 
schedule a Visit for the participant to return study products and disclose any 
Adverse Events or concomitant therapy changes. Refer to Section 13 for  further 
detail on classification of AEs and adverse device effects  (ADEs).  
2. During this Visit, if appropriate, participants will be asked to provide a urine 
sample for a pregnancy  test. 
3. If consent has not been withdrawn prior to the Study Visit, participants will be 
administered the FSFI study, Intercourse / Lubricant Use Study, and queried as 
needed to complete the Ring Use survey (in that  order).  
4. The participant will be queried regarding the reason for her withdrawal and the 
response will be recorded on the Early Termination CRF, record as much detail 
as possible (e.g. la ck of lubrication, too much lubrication, difficulty place/remove 
a ring, adverse event (related or unrelated to device),  etc.) 
5.4.4 Interim Follow -Up Call Schedule  
Each participant will be contact[CONTACT_585070] 7, 14, and 21 to assess their 
medical condition and to complete the Intercourse / Lubricant Use Survey. Participants 
will also be reminded to remove their current ring and replace with a fresh ring if they 
have not already done so. The study staff member administering the call will also query 
the participant to determine the date and time all ring exchanges (scheduled and un - 
scheduled) and temporary removals re -insertions, and if any assistance was required for 
insertion/removal for any of these exchanges/temporary removals.  
 
5.4.5 Terminal Follow -Up Procedure  
One (1) week after the last ring is removed, each participant will be contact[CONTACT_585071] a brief questionnaire. Each participant will also be 
reminded that she may contact [CONTACT_585072], directly or indirectly, with use of the 
ring. If the participant participated in the two -week open -label extension, study staff will 
query the participant to complete the ring us e log (see Section 5.4.8). If a participant is 
terminated early and returns to the clinic for a final visit (see above), all information and 
rings can be collected during this visit and an additional follow -up call is not  needed.  
 
5.4.6 FSFI (Female Sexual Funct ion Index)  Survey  
During both study visits (and an Early Termination Visit, if applicable), each participant will be 
given the FSFI Survey (see Appendix A).  
J3 Bioscience, Inc.  CONFIDENTIAL   
  
J3 Bioscience, 
Inc. Clinical Investigation Plan and Protocol CI03  
CI03 -CIP 
Rev. 0 2 
Page 35 of 60 A Clinical Investigation to Evaluate Efficacy of the J3  
Bioscience Lubricating Intravaginal Ring VR101 as a 
Personal Lubricant Device in Women  
  
5.4.7 Intercourse / Lubricant Use  Survey  
During Day 7, 14 and 21 Phone Calls and Visit 2, participants will be given a survey to 
assess:  
• Frequency of Intercourse since last  Visit/Call  
• Any uses of unapproved lubricants/sources of lubrication since the last  Visit/Call  
 
5.4.8 Ring Use Log  
Study staff shall complete a Ring Use log which details the date and time of all ring insertions 
and removals (scheduled and unscheduled, including temporary insertions and removals) by 
[CONTACT_585073]. This log should also note any time that 
assistance was required to place o r remove a ring, and record as much detail as possible 
regarding the nature of these events.  
 
NOTE: If a participant does not complete the [ADDRESS_769200] been used since Visit  2. 
 
5.4.9 Factors That May Influence the Outcome of the  Investigation  
Study Compliance  
If participants do not adhere to the indicated schedules (i.e., device use, surveys, study 
completion, visits to the clinic), then the data collected  in the investigation may be 
compromised or incomplete. Therefore, every attempt will be made to assure 
compliance with the visit and device exchange schedule. The treatment of incomplete 
data sets is addressed in the Statistical Analysis Plan (SAP).  
 
Participant Use of Products Excluded from the Study  
Neither clinical personnel nor the Sponsor will have the ability to directly monitor 
participants and ensure that they abstain from using products defined in the exclusion 
criteria (e.g., supplementary lubric ation). Participants will be queried in a repeated 
survey throughout the study as to whether they used any unapproved lubrication. A 
Concomitant Therapy assessment will be conducted at each Visit to determine if any 
disqualifying HRT or hormonal birth cont rol products (see Inclusion/Exclusion criteria) 
were used prior to or during the study.  
 
5.5 Monitoring  Plan  
The investigation will be monitored in accordance with the principles of Good Clinical 
Practice (GCP).” The monitoring schedule is as follows below.  
 
Initiation of the Investigation  
Each PI [INVESTIGATOR_585046].  
J3 Bioscience, Inc.  CONFIDENTIAL   
  
J3 Bioscience, 
Inc. Clinical Investigation Plan and Protocol CI03  
CI03 -CIP 
Rev. 0 2 
Page 36 of 60 A Clinical Investigation to Evaluate Efficacy of the J3  
Bioscience Lubricating Intravaginal Ring VR101 as a 
Personal Lubricant Device in Women  
  
Interim Monitoring Visit  
Interim monitoring of each site will occur after approximately [5 -10%] participants have 
enrolled in the study at each site (see Monitoring Plan), and again after [30 -40%] 
participants have enrolled at each site, an d after [30 -40%] participants have completed 
the study at each site. An additional monitoring visit will be conducted after the last 
participant at each site has completed the study. Additional visits may be scheduled to 
assure assessments are conducted ov er the duration of the study.  
 
Monitoring Closeout Visit  
The closeout visit will occur at each site following completion of the final clinical visit. 
Additional monitoring may be scheduled, at the discretion of the Sponsor, if protocol 
deviations or signif icant adverse events are reported or otherwise identified.  
 
NOTE: Study monitors must not be aware of any participant randomization assignments 
(maintained by [CONTACT_1034]) at any time before the Study is opened.  
 
5.6 Labeling  
VR101 device labeling is provided in Appendix B. VR101 labels will include the wording 
“for investigational use only” and other wording and markings to assure compliance with 
FDA and ISO [ADDRESS_769201] knowledge of 
which packaging identifiers correspond to either VR101 or the sham ring. The identity of 
admin istered rings will not be disclosed to any clinical staff prior to unblinding.  
 
After turning in their unused devices (which may be VR101 devices or sham rings), 
participants who elect to continue in the on -label extension will be provided with a new, 
labeled zip -lock bag (as described above) containing two VR101 devices.  
J3 Bioscience, Inc.  CONFIDENTIAL   
  
J3 Bioscience, 
Inc. Clinical Investigation Plan and Protocol CI03  
CI03 -CIP 
Rev. [ADDRESS_769202] been 
performed on VR101, where a total of 933 VR101 devices were used. No serious 
adverse device effects (SADEs) occurred in either clinical investigation (CI01 and CI02) 
study.  
 
6.3 Justification of Study  Endpoints  
6.3.1 FSFI -LD 
As a personal lubricant device, VR101 is intended to supplement the body’s natural 
lubrication to enhance the ease and comfort of intimate sexual activity. The Female 
Sexual Function Index (FSFI) is a survey validated to assess sexual function in women. 
The FSFI contains 19 questions, divided in to 6 characteristic domains: Desire, Arousal, 
Lubrication, Orgasm, Satisfaction, and Pain. Although all of these characteristics may be 
improved by [CONTACT_2363] a personal lubricant, only the Lubrication domain is directly relevant 
to a lubricant’s intended use.  
 
J3 Bio was asked by [CONTACT_585074]101 effic acy through analysis of individual 
improvement, rather than a comparison of group mean scores. Thus, we have proposed 
a threshold above which a participant’s LD will be deemed resolved to a clinically 
meaningful degree and the participant considered to be a study “responder” (LD 4.5 out 
of 6). In the FSFI cross -validation study (Wiegel 2005) a lubrication sub score threshold 
of 4.[ADDRESS_769203] achievable score above 4.35, the primary efficacy 
hypothesis will be supported if the proportion of participants reaching a score of 4.5 or 
better following 4 weeks of VR101 use exceeds that following 4 weeks of sham ring use. 
Participants will only be enr olled in the study if they score 1, 2 or 3 (out of 5) on all [ADDRESS_769204] 3 months, which contradicts one of the key study inclusion 
criteria. For this study to yield reliable results, only participants that demonstrate a 
willingness to attempt intercourse should be enrolled. The upper bound of 3 is justified 
because a score of 3 or less represents a non -satisfactory response to each question as 
follows:  
• Q7 and Q9: Lubrication “about half the time” or less during  intercourse.  
J3 Bioscience, Inc.  CONFIDENTIAL   
  
J3 Bioscience, 
Inc. Clinical Investigation Plan and Protocol CI03  
CI03 -CIP 
Rev. 0 2 
Page 38 of 60 A Clinical Investigation to Evaluate Efficacy of the J3  
Bioscience Lubricating Intravaginal Ring VR101 as a 
Personal Lubricant Device in Women  
  
• Q8 and Q10: Difficult, very difficult or extremely difficult to become/stay lubricated 
during  intercourse.  
6.3.2 Adverse Events / Adverse Device  Effects  
As in CI02, clinical staff will monitor and report all AEs throughout CI03 and attempt to 
determine their relatedness to VR101 use. This will continue to ensure the VR101 functions 
safely as a per sonal lubricant device. Refer to Section [ADDRESS_769205] Assessment  (CHA)  
A Clinical Hazard Assessment has been performed and is included as Appendix C.  
 
7.3 Risk -Benefit  Ratio  
A benefit/risk assessment is included in the Clinical Hazard Assessment (Appendix C). 
The assessment concludes that “Review of the benefits derived by [CONTACT_2363] V R101 and 
the risks inherent in its use results in a conclusion that the benefits of device use 
outweigh the risks inherent in anticipated end -use and misuse situations.”  
 
[ADDRESS_769206] y with the requirements of ICH E3, 
ICH E6, ICH E9, and with guidance from ICH E9 (R1), allowing the investigation to also support 
regulatory submissions and registrations in other countries or regions.  
 
The formal Statistical Analysis Plan (SAP) will be co mpleted prior to database lock and 
unblinding of the of the study data.  
 
8.1 Statistical  Hypotheses  
8.1.1 Primary Efficacy  
• The primary efficacy analysis will be a superiority comparison between the proportion of 
participants in each group who report FSFI -LD (lubrica tion domain composite) scores  of 
4.5 or greater after using VR101 or the sham ring for 4 weeks.  
 
• This endpoint will reflect changes in FSFI -LD from baseline (Day 0) to the study endpoint 
(Day 28 ± 2). Inclusion criteria were designed to ensure that all study participants enter 
the study at a dysfunctional level as outlined in Section 6.3. The null hypothesis to be 
tested is that similar numbers of women in each of the study groups will report FSFI -LD 
scores of 4.5 or greater (non -dysfunctional) after [ADDRESS_769207] for the difference between two 
proportions, α = 0.05, two -tailed. Rejection of the null hypothesis will be interpreted as 
support for the alternative hypothes is, that there is a non -random, statistically significant 
effect (efficacy) for VR101.  
 
HO: μVR101  = μsham  HA: μVR101  ≠ μsham  
 
8.1.2 Exploratory  
An exploratory analysis of individual changes in the Female Sexual Function Index (FSFI) total 
composite score (Rosen 2000) and its domains (Desire, Arousal, Lubrication, Orgasm, 
Satisfaction, and Pain) during 28 days of use will be conducted. Similar to the analyses 
conducted by [CONTACT_585075] 2000, changes in individual scores will be compared for the two groups 
using app ropriate parametric (independent -test) or nonparametric (Mann -Whitney) statistical 
methods.  
 
8.2 Analysis  Groups  
8.2.1 Target  population  
This is the stratum of subjects who are able to adhere to treatment, in other words, the subset of 
the broader population who would adhere to either treatment being compared, in which failure to 
adhere to treatment would not occur. The representative study target population is women with 
deficient  vaginal  moisture  / lubrication  who can independently  and consistentl y use a vaginal  ring, 
identified through inclusion and exclusion criteria and successful completion of the 4 -week 
treatment phase of the study.  
 
8.2.2 Full Analysis Set  (ITT)  
Includes all randomized subjects.  
 
8.2.[ADDRESS_769208] that is less biased and more interpretable and provides more 
information than naïve analysis of the per-protocol set. A complete demographic and baseline 
measure profile will be obtained for each participant at Enrollment (Day 0) and protocol 
compliance will be assessed weekly. Detailed explanations for non -compliance or failure to 
complete the study wil l be collected.  
 
8.3 Sample Size Determination (ICH E3; 9.7.2 ICH E9;  3.5) 
• As noted in Section 6.3.1, effect size and variability for this study were estimated from 
previous experience with VR101 and the literature on FSFI use in similar populations. 
The prima ry efficacy endpoint, group difference in proportion of subjects whose FSFI -LD 
scores exceed 4.5 (responders) at the end of the 4 -week treatment period assuming a 
Sham Group responder rate of 30% and a VR101 responder rate of at least 64%,  alpha  
= 0.01 was  used for power and sample size calculations.  
• The assumed effect size was based on previous studies with VR101 and a sham ring 
using self -reported measures of vaginal lubrication during intercourse (Section 6.3.1). 
The sample size needed to detect a 0.[ADDRESS_769209] size while maintaining the probability of 
correctly rejecting the null hypothesis when it is false (power = 1 – beta) was calculated 
using the power and sample size function for a test between two proportions in Minitab 
17 (Minitab 2017) computer sof tware for prospective study  design.  
• Based on the power curves generated using this information and expected dropout rates 
(Section 8.4), a minimum of 80 subjects randomized to each group (VR101 or sham) of 
the study will provide adequate power for the prim ary efficacy analysis and continued 
safety evaluation. Robustness of the proposed sample size is justified by [CONTACT_585076] -LD for this  study.  
J3 Bioscience, Inc.  CONFIDENTIAL   
  
J3 Bioscience, 
Inc. Clinical Investigation Plan and Protocol CI03  
CI03 -CIP 
Rev. 0 2 
Page 41 of 60 A Clinical Investigation to Evaluate Efficacy of the J3  
Bioscience Lubricating Intravaginal Ring VR101 as a 
Personal Lubricant Device in Women  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Robustness of the proposed sample size  
 
8.4 Expected Drop -Out Rates  
Based on experience with the VR101 in previous clinical investigation studies, we 
anticipate that approximately 70% of subjects screened for the study will meet 
inclusion/exclusion criteria and be enrolled, 95% of those enrolled will be randomized to 
treatment groups and is it estimated that of randomized subjects will compl ete the 
study, per protocol.  
Comparison p  
 
  
  
  
  
  
  
 
 
 
 
 
 
75 
   
 
 
 
Sample  
Size 
65 
  
  
 
 
 
  Power  
J3 Bioscience, Inc.  CONFIDENTIAL   
  
J3 Bioscience, 
Inc. Clinical Investigation Plan and Protocol CI03  
CI03 -CIP 
Rev. 0 2 
Page 42 of 60 A Clinical Investigation to Evaluate Efficacy of the J3  
Bioscience Lubricating Intravaginal Ring VR101 as a 
Personal Lubricant Device in Women  
 
 
 
Not 
meeting 
inclusion 
criteria 
N = ~72 
(30% of 
Screened)   
 
 
 
 
 
Figure 5. Estimation of participant distribution and drop -out rates  
 
8.5 Pass / Fail Criteria of the Clinical  Investigation  
Demonstration of a statistically significant difference (at a 95% confidence level) between 
the study groups for propo rtions of subjects scoring 4.5 or higher on the FSFI -LD following 
the 4 -week treatment phase.  
 
8.6 Adjustment for Multiplicity  
No adjustment for multiplicity is planned as only one hypothesis will be tested.  
 
8.7 Disposition of Missing Data (ICH E3; 9.7.1, [IP_ADDRESS] ICH E9; 5.3. EMA 
Guideline on Missing Data in Confirmatory Clinical Trials, ICH E9  (R1) 
addendum)  
8.7.1 Prevention of Missing  Data  
• Prevention of missing data is a primary aim of this study design. Subjects will  be 
counseled at enrollment on the importan ce of completing the study  and 
Screened  
N = ~228  
Enrolled, Randomized  
(ITT)  
N = ~160 (70% of 228)  
    
Early  
Termination 
N = ~8 
 
 
Per Protocol Completers 
N = ~ 150 (95% of 160)  
J3 Bioscience, Inc.  CONFIDENTIAL   
  
J3 Bioscience, 
Inc. Clinical Investigation Plan and Protocol CI03  
CI03 -CIP 
Rev. 0 2 
Page 43 of 60 A Clinical Investigation to Evaluate Efficacy of the J3  
Bioscience Lubricating Intravaginal Ring VR101 as a 
Personal Lubricant Device in Women  
  
communicating all issues and concerns to the study coordinator. In turn, the 
study coordinator will provide a “safe” place for disclosure of intent to withdraw 
from the study so that an Early Termination visit and final outcome measures can 
be collected prior to withdrawal of consent. As long as patient safety is assured, 
non-compliance will not require early  discontinuation.  
• The importance of completeness and quality of data and standardized 
procedures for handling potential dropouts will be emphasized during directed 
training of investigators and clinic/study personnel. Attrition will not be 
encouraged.  
• Case report forms (CRFs) will be designed to capture relevant background 
information as wel l as objective reasons for early discontinuation when it cannot 
be prevented.  
8.7.2 Incentive to  Complete  
• Under the FDA guidance for payment and reimbursement to research subjects, 
(January 2018) the sponsor will provide a study completion bonus equal to the 
payment for one regular study visit for subjects who complete the study per 
protocol (with no missing  data).  
• Participants who complete the 4 -week double -blind study will be given an 
opportunity to continue in a 2 -week open -label extension where they will be 
guaranteed to receive  VR101.  
8.7.3 Unavoidable Loss of  Data  
• It is understood that data may still be missing, for anticipated and unanticipated 
reasons (intercurrent events) that arise during the study. As no universally 
applicable methods for handling missing val ues are recommended in the 
guidance documents, methods for handling missing values in this study will be 
justified by [CONTACT_585077]. An investigation will be made 
concerning the sensitivity of the results of analysis to the method of handling 
missing  values.  
It is expected that any study subject who begins one of the treatment arms 
following randomization will be included in the primary efficacy analysi s. As 
noted, randomization criteria require all inclusion criteria are met and that 
screening (Day 0) FSFI -LD scores are complete. The primary efficacy outcome, 
proportion of subjects who have a “functional” score of 4.[ADDRESS_769210] randomization FSFI -LD score.  
 
• Where unavoidable, participants who cannot complete 28 days of treatment will 
be scheduled for an End of Treatment visit so that final FSFI -LD scores can be 
collected prior to withdrawal of  consent.  
J3 Bioscience, Inc.  CONFIDENTIAL   
  
J3 Bioscience, 
Inc. Clinical Investigation Plan and Protocol CI03  
CI03 -CIP 
Rev. 0 2 
Page 44 of 60 A Clinical Investigation to Evaluate Efficacy of the J3  
Bioscience Lubricating Intravaginal Ring VR101 as a 
Personal Lubricant Device in Women  
  
 
• For subjects who must drop out prior to providing study endpoint efficacy data 
the reason for early discontinuation will be ascertained and recorded in the CRF. 
Prior to data lock and unblinding of the randomization c ode the status and  quality 
of each subject’s study data will be assessed by [CONTACT_456]’s data quality team. 
The disposition and assignment of each subject to a study population analysis 
group will occur prior to  unblinding.  
 
• Where final FSFI -LD data are not available and exceed greater than 5% of the 
values for comparison, a mixed model regression analysis that includes the 
dependent variable and one or more auxiliary variables that reflect plausible 
assumptions around the uncertainty due to missing d ata will be conducted and 
subjected to sensitivity  analysis.  
8.7.4 Missing Data by  [CONTACT_223909]  
• The reasons why data are missing and whether there are systematic differences in the 
patterns of missing data across the treatment arms will also be summarized. Group 
differences will be examined following unblinding using a data summary table for the 
analysis groups. This information will be used to determine the most appropriate 
sensitivity analyses to test assumptions of the mixed model regression approach for 
missing  data. 
8.[ADDRESS_769211] disposition, assignment 
to subgroups for data analysis, method of dealing with any missing data, and relevant 
sensitivity analyses  for alternate approaches.  
9 DATA COLLECTION AND  MANAGEMENT  
Paper CRFs (Case Report Forms) will be used for data collection during the  
study. Paper CRFs will be printed on 2 -part NCR (no carbon required) with a copy 
retained by [CONTACT_585078].  
 
Data from CRFs will be transcribed into an electronic database by [CONTACT_585079] -entry following study opening. Since the hand -written original CRF copi[INVESTIGATOR_014]  
J3 Bioscience, Inc.  CONFIDENTIAL   
  
J3 Bioscience, 
Inc. Clinical Investigation Plan and Protocol CI03  
CI03 -CIP 
Rev. [ADDRESS_769212], Sponsor/ analyst bias does not present concern to 
the study, provided double data -entry and an additional, independent data audit of 
database transfer is performed.  
 
10 AMENDMENTS TO THE  CIP 
Amendments to the CIP require written authorization of the Sponsor before the y are 
recommended to the IRB(s) for approval. No changes will be made to the devices or the 
CIP without Sponsor and IRB approval.  
 
To revise the CIP, the written proposed changes will be reviewed and approved by [CONTACT_585080], 
treatment procedures, assessment methods, data analysis, or any other procedures 
documented in the CIP may be made, or any additional information may be added.  
 
11 DEVIATIONS FROM THE  CIP 
11.1 Acceptable Circumstances for  Deviations to the  CIP 
Investigators shall not deviate from this CIP, except under the following circumstances:  
• Deviations may be made with prior approval of the Sponsor if made in deference 
to participant's rights, safety and well -being, or the scientific integrity of the 
clinical  investigation.  
• Under emergency circumstances, deviations from the CIP to protect the rights, 
safety and well -being of human participants may proceed without prior approval 
of the Sponsor and the  IRB. 
 
Such deviations sh all be documented and reported to the Sponsor and the IRB as soon 
as possible.  
 
11.2 Procedure for Disqualification and Replacement of a  Principal 
Investigator  
[INVESTIGATOR_585047] (Principal Investigator) or Sub -PI [INVESTIGATOR_585048], and/or consistently endanger participant's rights, safety and 
wellbeing, or the scientific integrity of the clinical investigation, may be removed from the 
investigation.  
12 DEVICE ACCOUNTABILITY  
12.1 Access to  Devices  
Investigational rings (VR101 device s and sham rings) will be stored in a locked cabinet 
that will only be accessible by [CONTACT_978] [INVESTIGATOR_32528]. Only the study coordinator 
and designated staff members will have access to this cabinet and to the Device 
Accountability log, which contains  the list of device numbers assigned to each subject.  
J3 Bioscience, Inc.  CONFIDENTIAL   
  
J3 Bioscience, 
Inc. Clinical Investigation Plan and Protocol CI03  
CI03 -CIP 
Rev. 0 2 
Page 46 of 60 A Clinical Investigation to Evaluate Efficacy of the J3  
Bioscience Lubricating Intravaginal Ring VR101 as a 
Personal Lubricant Device in Women  
  
12.2 Physical Location of Investigational  Devices  
The Sponsor shall keep records to document the physical location of all investigational 
devices from shipment of investigational devices and s hams to the investigation sites 
until return or disposal.  
 
12.3 Use of  Devices  
Investigational devices and sham rings shall only be used in a manner specified by [CONTACT_585081].  
 
12.4 Distribution of Devices from the Sponsor to Clinical  Sites  
The Sponsor will deliver a specified number of VR101 and sham samples to each 
clinical site. Each clinical site will maintain Device Accountability Logs (see below), to 
which an entry must be made each time a VR101 or sham ring is given to a particip ant, 
or unused spare or used VR101 or sham ring is returned to the clinic by a participant.  
 
12.5 Device Accountability Log  
The principal investigator, study coordinator or an authorized designee shall keep a 
Device Accountability Log for VR101 and sham rings w hich shall include:  
• The date of receipt and number of devices received from the  Sponsor.  
• The lot number or any other unique identifier of the rings  received.  
• The expi[INVESTIGATOR_585049], if  applicable.  
• The number and unique IDs of rings administe red to each participant, along with 
their unique participant identifier, and the date  issued.  
• The number of unused rings returned by [CONTACT_20908], along with their  unique 
participant identifier, device identifiers and the  date.  
 
[ADDRESS_769213] be reported to the 
Sponsor, IRB and/or FDA as they occur throughout the study (see below and in Sections 13.7 
through 13.11).  
 
SAEs and SADEs (as defined be low) are to be reported to the Sponsor and IRB within 
24 hours of the PI [INVESTIGATOR_585050].  
J3 Bioscience, Inc.  CONFIDENTIAL   
  
J3 Bioscience, 
Inc. Clinical Investigation Plan and Protocol CI03  
CI03 -CIP 
Rev. 0 2 
Page 47 of 60 A Clinical Investigation to Evaluate Efficacy of the J3  
Bioscience Lubricating Intravaginal Ring VR101 as a 
Personal Lubricant Device in Women  
  
All ADEs (as defined below) are to be reported to the Sponsor within 5 days of their occurrence 
if study staff determines that they are possibly, probably or definitely related to use of an 
investigational device (VR101 or sham ring).  
 
13.1 Definitions  
Definitions below were constructed based on guidance from and definitions provided  in 
ISO [ZIP_CODE] and 21 CFR  812.3.  
 
Adverse Event (AE) : Any u ntoward medical occurrence, unintended disease or injury, or 
untoward clinical signs (including abnormal laboratory findings) in subjects, users or 
other persons, whether or not related to VR101 use.  
 
Serious Adverse Event (SAE) : An AE that leads to:  
• Death  
• A serious deterioration in the health of the participant, that resulted in any of the 
following:  
- A life -threatening illness or  injury  
- A permanent impairment of a body structure or a body  function  
- In-patient or prolonged  hospi[INVESTIGATOR_059]  
- Medical or sur gical intervention to prevent life -threatening illness or injury 
or permanent impairment to a body structure or a body  function  
• Fetal distress, fetal death or a congenital abnormality or birth  defect.  
 
Adverse Device Effect (ADE) : An AE related to use of V R101.  
Serious Adverse Device Effect (SADE) : An ADE that results in any of the consequences 
characteristic of a SAE.  
 
Unanticipated Serious Adverse Device Effects ([LOCATION_003]DE) : Any SADE that was not 
previously identified in nature, severity, or degree of incidence in this CIP or application 
(including a supplementary plan or application), or any other unanticipated serious 
problem associated with a device that relates to the rights, safety, or welfare of subjects.  
 
Use Error : Act or omission of an act that  results in a different response to VR101 than 
intended or than expected by [CONTACT_28024].  
Device Deficiency : Inadequacy of a medical device (VR101) with respect to its identity, 
quality, durability, reliability, safety or performance.  
 
The following table, cop ied from ISO [ZIP_CODE]:2011, summarizes how adverse events will 
be categorized.  
J3 Bioscience, Inc.  CONFIDENTIAL   
  
J3 Bioscience, 
Inc. Clinical Investigation Plan and Protocol CI03  
CI03 -CIP 
Rev. 0 2 
Page 48 of 60 A Clinical Investigation to Evaluate Efficacy of the J3  
Bioscience Lubricating Intravaginal Ring VR101 as a 
Personal Lubricant Device in Women  
  
 
 
 
13.2 Anticipated Adverse Events  (AE) 
Following is a list of adverse events that may occur during CI03:  
• Discomfort/pain/pressure (vaginal,  abdominal)  
• Vaginal/cervical tissue  irritation  
• Itching  
• Burning  
• Vaginal discharge/excess vaginal secretion  
• Malodor  
• Non-menstrual vaginal/cervical  bleeding  
• Nausea  
• Coital  problems  
• Penis discomfort (pain, itching,  irritation)  
• Increased urinary  urge 
• Increased  incontinence  
• Constipation  
• Bowel  obstruction  
• Infection (e.g., Bacterial Vaginosis, Yeast Infection, Urinary Tract  Infection)  
 
13.3 Anticipated Adverse Device Effects  (ADE)  
Following is a list of adverse events that may be related to the use of VR101 or the 
sham:  
• Device -related  discomfort/pain  

J3 Bioscience, Inc.  CONFIDENTIAL   
  
J3 Bioscience, 
Inc. Clinical Investigation Plan and Protocol CI03  
CI03 -CIP 
Rev. 0 2 
Page 49 of 60 A Clinical Investigation to Evaluate Efficacy of the J3  
Bioscience Lubricating Intravaginal Ring VR101 as a 
Personal Lubricant Device in Women  
  
• Device -related  crampi[INVESTIGATOR_007]  
• Device -related vaginal  itching/burning/irritation  
• Device -related non -menstrual  bleeding  
• Toxic -shock  syndrome  
• Ring adherence to the vaginal  wall 
• Inability of user to remove the  ring 
• Bowel  obstruction  
• Ring breakage that causes  injury  
• Device -related  infection  
• Device -related vaginal/cervical/urethral  irritation/inflammation  
• Device -related  malodor  
• Device -related vaginal discharge (e.g., excessive lubrication /  secretions)  
• Device -related  incontinence  
• Intermittent  Nausea  
• Intermittent  Headache  
• Physical interference with other intravaginal or intrauterine  devices  
 
Some anticipated ADEs listed above are hypothetical, and some have been observed 
clinically. Refer to reports for CI01 and CI02 for a complete list of observed ADEs (either 
definitely or potentially related to VR101 use) and their frequency.  
 
13.[ADDRESS_769214] of device deficiencies that may be related to failure of VR101 or sham 
to meet its acceptance criteri a: 
• Outer polymeric ring is damaged - no release of  contents  
• Outer polymeric ring is damaged - release of  contents  
• Ring weld fails - no release of  contents  
• Ring weld fails - release of contents  
• Device has rough  surfaces  
• Device will not stay in  place  
• Device is contaminated (on removal from package, extraneous matter is 
observed)  
• Device is too  rigid 
• Device is too  soft 
• Device is too  large  
• Device is too  small  
• Device is too  slippery  
• Device cannot be easily  inserted  
• Device cannot be easily  removed  
• Instructions are missing and/or hard to  follow  
• Packaging is difficult to open  
• Device is not  biocompatible  
J3 Bioscience, Inc.  CONFIDENTIAL   
  
J3 Bioscience, 
Inc. Clinical Investigation Plan and Protocol CI03  
CI03 -CIP 
Rev. [ADDRESS_769215] Assessment, the residual risks associated with the above device 
deficiencies are adequately mitigated and/or are outweighed by [CONTACT_585082]101.  
 
13.5 Possible Use Errors  
Following are possible use errors, which do not indicate failure of VR101 or sham to 
meet its specifications:  
• Placement of ring in the urinary  tract 
• Placement of ring in the anus or  colon  
• Oral contact [CONTACT_585083]  
• Use of damaged  device  
• Use of contaminated device (packaging  damaged)  
• Use of user -contaminated  device  
• Use of user -damaged  device  
 
13.6 Unanticipated Serious Adverse  Events  
Unanticipated Serious Adverse Event s ([LOCATION_003]Es) are adverse events occurring during the 
course of a clinical study that meet the following criteria:  
• Serious  
• Unanticipated  
• Definitely, probably, or possibly related to the investigational device or  sham  
An unanticipated adverse event is any adverse event occurring in one or more subjects 
participating in a research protocol, whose nature, severity, or frequency is not 
consistent with either:  
• The unknown or foreseeable risk of adverse events associated with the 
procedures involved in the resea rch that are described in the protocol related - 
documents, such as the IRB -approved research protocol, and applicable 
investigator brochure, and the current IRB -approved informed consent document, 
and other relevant sources of information, such as product labeling, including 
instructions for  use. 
• The expected natural progression of any underlying disease or condition of the 
participant(s) experiencing the adverse  event.  
 
13.[ADDRESS_769216]  Reporting  
The FDA’s Investigational Device Exemption (IDE) regulations define an unanticipated 
adverse device effect (UADE) as, “any serious adverse effect on health or safety or any 
life-threatening problem or death caused by, or associated with, a device , if that effect, 
problem, or death was not previously identified in nature, severity, or degree of incidence 
in the investigational plan or application (including a supplementary plan or application),  
J3 Bioscience, Inc.  CONFIDENTIAL   
  
J3 Bioscience, 
Inc. Clinical Investigation Plan and Protocol CI03  
CI03 -CIP 
Rev. 0 2 
Page 51 of 60 A Clinical Investigation to Evaluate Efficacy of the J3  
Bioscience Lubricating Intravaginal Ring VR101 as a 
Personal Lubricant Device in Women  
  
or any other unanticipated serious problem associated with a device that relates to the 
rights, safety, or welfare of subjects” (21 CFR 812.3(s)).  
 
UADEs must be reported by [CONTACT_585084], as described below:  
• Investigators are require d to submit a report of a UADE to the Sponsor and the 
reviewing IRB as soon as possible, but in no event later than [ADDRESS_769217] learns of the event (§ 812.150(a)(1). The FDA 
requirement is for reporting within 10 days, which  has been reduced by 2 days to 
allow more time for  investigation).  
• Sponsor must immediately conduct an evaluation of a UADE and must report the 
results of the evaluation to FDA, all reviewing IRBs, and participating 
investigators within [ADDRESS_769218] (§§ 812.46(b),  812.150(b)(1)).  
• [From 21 CFR 812.46 (b)(2)]: A Sponsor who determines that an unanticipated 
adverse device effect presents an unreasonable risk to subjects shall terminate 
all investigations  or parts of investigations presenting that risk as soon as 
possible. Termination shall occur not later than [ADDRESS_769219] received  notice.  
 
13.7.2  Adverse Even t Reporting  
Any adverse event (as identified above), whether anticipated or not, shall be reported by 
[CONTACT_585085], but in no case later than 5 days 
from the date of its occurrence.  
 
AE collection will begin after con sent has been obtained and continue until the final visit. 
Every AE or symptom will be recorded in the CRF and will include:  
 
• Nature (Brief  Description)  
• Date and Time of  onset  
• Date and Time of  resolution  
• Severity  
• Probability of relationship to study  procedures  
• Probability of relationship to the investigational  device  
• Action  Taken  
• Outcome  
 
Based on the occurrence and intensity of AEs, coupled with results of any other 
observations, the Investigator, at his/her discretion and following discussion with t he 
Sponsor, may decide to withdraw a subject or prematurely end the study for reasons of  
J3 Bioscience, Inc.  CONFIDENTIAL   
  
J3 Bioscience, 
Inc. Clinical Investigation Plan and Protocol CI03  
CI03 -CIP 
Rev. [ADDRESS_769220] igator.  
 
13.8 Resumption of Terminated  Studies  
Since the device is a non -significant risk (NSR) device, the Sponsor is required to seek 
IRB approval, but not necessarily FDA approval to resume a terminated investigation. 
However, if the investigation was terminated under 21 CFR 812.46(b)(2) (see section  
13.7.1 above), FDA and IRB approval are required to resume a terminated study.  
 
13.[ADDRESS_769221] led to a medical 
occurrence:  
• If either suitable action had not been  taken,  
• If intervention had not been made,  or 
• If circumstances had been less fortunate, shall be documented in the Sponsor’s 
records.  
Any device deficiencies (as identified above) shall be reported by [CONTACT_585086], but in no case later than 5 days from the date of their 
occurrence.  
 
13.10  Follow -Up for Adverse  Events  
Participants experiencing device -related adverse events will be followed by [CONTACT_585087] n site until the clinical situation associated with the device -related 
adverse event is resolved, stabilizes or becomes chronic.  
 
13.11  Communication  Plan  
Adverse events at any of the study sites will be brought to the PI's attention when 
identified. Those that are "reportable" events will be submitted to IRBs. The Sponsor will 
discuss any adverse events that impact the investigation with staff members at all study 
sites.  
Any approved changes to the investigational plan will be communicated to the PI [INVESTIGATOR_585051] -approved study sites. Any changes to procedures will require 
training to ensure that new protocol requirements are met.  
J3 Bioscience, Inc.  CONFIDENTIAL   
  
J3 Bioscience, 
Inc. Clinical Investigation Plan and Protocol CI03  
CI03 -CIP 
Rev. [ADDRESS_769222], performance monitoring, auditing, recording, analysis and reporting of clinical 
investigations tha t provides assurance that the data and reported results are credible 
and accurate, and that the rights, integrity, and confidentiality of the investigation 
participants are protected.  
 
A qualified clinician will make any medical decisions and decide what m edical care is 
given (if applicable). Each individual involved in conducting the investigation should be 
qualified by [CONTACT_8640], training, or experience to perform his or her respective tasks. The 
investigation  can only start at the Investigator's  site after the relevant  Institutional  Review 
Board has approved the protocol, the Informed Consent Forms and other written 
information is provided to the participants, all study personnel have been suitably 
trained, and contractual arrangements identifying responsibilities are  signed.  
 
All participants will be informed that participation is voluntary and that they can cease 
participation at any time without giving a reason and without penalty or loss of benefits to 
which they are entitled. Howeve r, the Investigator should try to exclude the possibility 
that a participant withdraws voluntarily because of an Adverse Event.  
 
To participate, the participant must give consent prior to enrollment in the investigation. 
This consent must be given in writi ng. The person who conducts the informed consent 
discussion must also sign the ICF. With consent, the participant confirms that their 
participation is voluntarily and that they will follow the instructions of the investigator and 
answer the questions asked . Signatures must be personally provided and dated.  
Prior to participation in the investigation, the participant should receive a copy of the 
signed and dated written ICF and any other pertinent written information. The Consent 
form must include all elemen ts required by [CONTACT_2371], local regulations, Good Clinical Practice 
and International Conference on Harmonization (ICH) guidelines, and Food and Drug 
Administration (FDA) requirements as well as any investigation -specific items.  
 
Neither the Investigator, nor th eir staff should coerce or unduly influence a participant to 
participate in, or continue participating in, the investigation. Ample time must be allowed 
for the participant to make his or her decision to participate in an investigation and to 
make further enquiries about the investigation.  
J3 Bioscience, Inc.  CONFIDENTIAL   
  
J3 Bioscience, 
Inc. Clinical Investigation Plan and Protocol CI03  
CI03 -CIP 
Rev. [ADDRESS_769223]  (IRB)  
Institutional Review Boards safeguard the rights, safety, and well -being of investigation 
participants. Thus, the IRB will obtain, and document receipt of, the following documents 
provided by [CONTACT_1034]:  
• Clinical Investigation Protocol and, if applicable, substantial  amendments.  
• Template Informed Consent Form and any other inform ation that the Investigator 
proposes for use in the  investigation.  
• Participant recruitment procedures (e.g.,  advertisements).  
• Written information to be provided to participants (if  applicable).  
• Investigator's Brochure.  
• Safety  information.  
• Information about  payments and compensation available to  participants.  
 
In addition, the PI [INVESTIGATOR_585052]:  
• Investigator's current curriculum vitae and/or other documentation  evidencing 
qualifications.  
• Any other documents that the IRB may need to fulfill its  responsibilities.  
 
J3 Bio (Sponsor) will request that the IRB for the site, or other regulatory authorities, 
where applicable, provide its written procedures and membership or voting lists. The IRB 
shall maintain records of its activiti es and minutes of its meetings. All relevant records 
pertaining to the investigation shall be kept for a period of at least five (5) years after the 
completion of the investigation and will be made available to regulatory authorities on 
request.  
 
14.[ADDRESS_769224] of the 
investigation at an investigation center. If a team of individuals at the site conducts the 
investigation, the Investigator is the respo nsible leader of the team and will be called 
Principal Investigator (PI). The PI [INVESTIGATOR_214068] a signed list of appropriately qualified 
persons to whom he/she has delegated significant investigation -related duties, which 
must be specified. A copy is held i n the site's files and the original will be sent to the 
Sponsor (e.g., Delegation of Authority).  
 
14.2.2  A Sub -Investigator (Sub -I, e.g., Medical Professional, Associates) 
The Sub -Investigator is any individual member of the clinical investigation team 
designated  and supervised by [CONTACT_978] [INVESTIGATOR_585053] -related procedures and/or make important investigation -related  decisions.  
J3 Bioscience, Inc.  CONFIDENTIAL   
  
J3 Bioscience, 
Inc. Clinical Investigation Plan and Protocol CI03  
CI03 -CIP 
Rev. 0 2 
Page 55 of 60 A Clinical Investigation to Evaluate Efficacy of the J3  
Bioscience Lubricating Intravaginal Ring VR101 as a 
Personal Lubricant Device in Women  
  
 
14.2.3  Sponsor  
The Sponsor is an individual or organization that takes responsibility for the initiation 
and/or implementation of a clinical investigation. J3 Bio accepts the responsibilities of 
the Sponsor.  
 
14.2.[ADDRESS_769225] 
operating procedures, Good Clinical Practice (GCP) and applicable regulatory 
requirements, and ensures t hat the investigation data are accurate, complete and 
verifiable from source document collection forms.  
 
Before the investigation starts at the investigative site, J3 Bio's appointed monitor will 
ensure that the investigation site has sufficient capacity a nd equipment to perform the 
investigation. At agreed upon times, the Investigators will permit the monitor to check 
and verify investigation documentation (source document verification), including the CRF 
and other information prepared for J3 Bio (e.g., lo gs and reports). The Investigator shall 
make corrections, amendments, or clarifying statements where necessary. Investigation - 
related medical decisions are the responsibility of a qualified clinician or medically 
qualified delegate. A written report will be completed by [CONTACT_585088] J3 Bio after each 
visit. 
 
The Sponsor and IRB require C urriculum Vitae and other relevant documents confirming 
the qualifications of the PI [INVESTIGATOR_34511] -Investigators. Any previous training in the principles 
of Good Clinical Prac tice (GCP) or experience obtained from work with clinical 
investigations and participant care should be described in the Curriculum Vitae. When 
personnel changes are made, the relevant documentation (e.g., Delegation of Authority) 
must be updated before a new member of the team may perform assigned investigation - 
related activities.  
 
[ADDRESS_769226] of this study will not deliberately solicit participation from nor enroll 
participants from vulnerable populations.  
 
16 SUSPENSION OR PREMATURE TERMINATION OF THE 
CLINICAL INVESTIGATION (STOPPI[INVESTIGATOR_224513])  
The investigation may be prematurely terminated by [CONTACT_4707], 
regulatory authorities, or the Sponsor, if for example, the perception of the risk to bene fit 
J3 Bioscience, Inc.  CONFIDENTIAL   
  
J3 Bioscience, 
Inc. Clinical Investigation Plan and Protocol CI03  
CI03 -CIP 
Rev. 0 2 
Page 56 of 60 A Clinical Investigation to Evaluate Efficacy of the J3  
Bioscience Lubricating Intravaginal Ring VR101 as a 
Personal Lubricant Device in Women  
  
ratio becomes unfavorable for the continuation of the investigation. A decision to cease 
the investigation in all centers is binding to all Investigators. If the investigation is 
prematurely terminated or suspended for any reason the Inv estigator shall promptly 
inform the participants, ensuring appropriate therapy and follow -up for all participants 
and informing the regulatory authorities (where appropriate) and the institution where the 
investigation was being performed.  
 
Further, the Sp onsor may terminate the study at any time in a center:  
• if the investigator is non -compliant with the protocol, the regulatory requirements 
or the  ICH-GCP;  
• if the CRF completion or drug accountability is inadequate, and the investigator is 
unable to take corrective action in any of these cases,  or; 
• in case of failure to recruit  subjects.  
 
If an unwanted effect (adverse reaction) is considered severe by [CONTACT_585089], the study will be discontinued after agre ement with 
the Sponsor.  
The entire study may be terminated for medical reasons. In addition, the Sponsor retains 
the right to end the study at any time if the study cannot be carried out as agreed upon 
in the study protocol. In case of premature termination, the Investigators, IRBs and 
regulatory authorities will be informed by [CONTACT_16049].  
The Sponsor also reserves the right to terminate the study at any time for administrative 
reasons. The Sponsor will not reimburse the Investigator for the eval uation of subjects if 
the evaluations are conducted in a manner other than that specified in this protocol.  
 
[ADDRESS_769227] with this study (such as patent ownership, 
royalties, or financial gain greate r than the maximum allowable by [CONTACT_1385]) must 
fully disclose the nature of the conflict of interest in accordance with Sponsor policies 
and applicable federal, state, and local laws and regulations.  
 
[ADDRESS_769228] Operating 
Procedures (SOPs) or Good Clinical Practice (GCP) documents that identify the 
responsibilities of the Sponsor, Investigator, a nd Monitor.  
 
20 BIBLIOGRAPHY  
Bachman GA, Notelovitz M, Gonzalez, SJ, Thompson, C, Morecraft , BA. “Vaginal 
Dryness in Menopausal Women: Clinical characteristics and Nonhormonal Treatment.” 
Clinical Practice in Sexuality, 1991; 7(9): 25 -32. 
 
Bachmann GA, Notelovitz, M, Kelly, SJ, Owens, A, Thompson, C. “Long Term 
Nonhormonal treatment of Vaginal D ryness.” Clinical Practice in Sexuality, 1992; 8(8/9): 
3-8. 
 
Minitab 17 Statistical Software (2010). [Computer software]. State College, PA: Minitab, 
Inc. ( www.minitab.com ). 
 
Rosen R, Brown C, Heiman J, Leiblum S,  Meston C, Shabsigh R, Ferguson D, 
D’Angostino R Jr. “The Female Sexual Function Index (FSFI): a multidimensional self - 
report instrument for the assessment of female sexual function.” Journal of Sex & Marital 
Therapy, 2000 Apr -Jun; 26(2): 191 -208. 
 
Wiegel  M, Meston C, Rosen R. “The Female Sexual Function Index (FSFI): Cross - 
Validation and Development of Clinical Cutoff Scores.” Journal of Sex & Marital Therapy , 
2005; 31(1), 1 -20. 
J3 Bioscience, Inc.  CONFIDENTIAL   
  
J3 Bioscience, 
Inc. Clinical Investigation Plan and Protocol CI03  
CI03 -CIP 
Rev. 0 2 Page  
58 of 60 A Clinical Investigation to Evaluate Efficacy of the J3  
Bioscience Lubricating Intravaginal Ring VR101 as a 
Personal Lubricant Device in Women  
 
Appendix A  
FSFI Survey and Scoring Method  
 
(Note: Appendix A is 10 pages long including this page)  
Page 1 (of 5)   
 Female Sexual Function Index (FSFI) © 
 
 
Subject  Identifier    Date     
 
 
INSTRUCTIONS: These questions ask about your sexual feelings and responses 
during the past 4 weeks . Please answer the following questions as honestly and 
clearly as possible. Your responses will be kept completely confidential. In 
answering these questions  the following definitions apply:  
 
Sexual activity  can include caressing, foreplay, masturbation and vaginal intercourse.  
 
Sexual intercourse  is defined as penile penetration (entry) of the vagina.  
 
Sexual stimulation  includes situations like foreplay with  a partner, self -stimulation 
(masturbation), or sexual fantasy.  
 
CHECK ONLY  ONE BOX PER QUESTION.  
 
Sexual desire  or interest  is a feeling that includes wanting to have a sexual 
experience, feeling receptive to a partner's sexual initiation, and thinking or 
fantasizing about having sex.  
 
1. Over the past [ADDRESS_769229]?  
 
Almost always or always  
Most times (more than half the time) 
Sometimes (about half the time)  
A few times (less than half the time) 
Almost never or never  
 
2. Over the past 4 weeks, how would you rate your level (degree) of sexual desire 
or interest?  
 
Very high 
High 
Moderate 
Low 
Very low or none at all  
Page 2 (of 5)   
 Sexual arousal is a feeling that includes both physical and mental aspects of sexual 
excitement. It may include feelings of warmth or tingling in the genitals, lubrication 
(wetness), or muscle contractio ns. 
 
3. Over the past 4 weeks, how often did you feel sexually aroused ("turned on") 
during sexual activity or  intercourse?  
 
No sexual activity 
Almost always or  always  
Most times (more than half the time) 
Sometimes (about half the time)  
A few times (less than half the time) 
Almost never or never  
 
4. Over the past 4 weeks, how would you rate your level of sexual arousal ("turn 
on") during sexual activity or  intercourse?  
 
No sexual activity 
Very high  
High 
Moderate 
Low 
Very low or none at all  
 
5. Over the past 4 weeks, how confident were you about becoming sexually 
aroused during sexual activity or  intercourse?  
 
No sexual activity 
Very high confidence 
High confidence 
Moderate confidence 
Low confidence  
Very low or no confidence  
 
6. Over the past [ADDRESS_769230] you been satisfied with your arousal 
(excitement) during sexual activity or  intercourse?  
 
No sexual activity 
Almost always or  always  
Most times (more than half the time) 
Sometimes (about half the time)  
A few times (less than half the time) 
Almost never or never  
Page 3 (of 5)   
 7. Over the past 4 weeks, how often did you become lubricated ("wet") during 
sexual activity or  intercourse?  
 
No sexual activity 
Almost always or  always  
Most times (more than half the time) 
Sometimes (about half the time)  
A few times (less than half the time) 
Almost never or never  
 
8. Over the past 4 weeks, how difficult was it to become lubricated ("wet") during 
sexual activity or  intercourse?  
 
No sexual activity  
Extremely difficult or impossible 
Very difficult  
Difficult 
Slightly difficult 
Not difficult  
 
9. Over the past 4 weeks, how often did you maintain your lubrication ("wetness") 
until completion of sexual activity or  intercourse ? 
 
No sexual activity 
Almost always or  always  
Most times (more than half the time) 
Sometimes (about half the time)  
A few times (less than half the time) 
Almost never or never  
 
10. Over the past 4 weeks, how difficult was it to maintain your lubrication 
("wetness") until completion of sexual activity or  intercourse?  
 
No sexual activity  
Extremely difficult or impossible 
Very difficult  
Difficult 
Slightly difficult 
Not difficult  
Page 4 (of 5)   
 11. Over the past 4 weeks, when you had sexual stimulation or intercourse,  how 
often did you reach orgasm (climax)?  
 
No sexual activity 
Almost always or  always  
Most times (more than half the time) 
Sometimes (about half the time)  
A few times (less than half the time) 
Almost never or never  
 
12. Over the past 4 weeks, when you had sexual stimulation or intercourse,  how 
difficult was it for you to reach orgasm (climax)?  
 
No sexual activity  
Extremely difficult or impossible 
Very difficult  
Difficult 
Slightly difficult 
Not difficult  
 
13. Over the past 4 weeks, ho w satisfied were you with your ability to reach orgasm 
(climax) during sexual activity or  intercourse?  
 
No sexual activity 
Very satisfied 
Moderately satisfied  
About equally satisfied and dissatisfied 
Moderately dissatisfied  
Very dissatisfied  
 
14. Over the pas t [ADDRESS_769231] you been with the amount of 
emotional closeness during sexual activity between you and your  partner?  
 
No sexual activity 
Very satisfied 
Moderately satisfied  
About equally satisfied and dissatisfied 
Moderately dissatisfied  
Very dissatisfied  
 
 15. Over the past [ADDRESS_769232] you been with your sexual 
relationship with your partner?  
 
Very satisfied 
Moderately satisfied  
About equally satisfied and dissatis fied 
Moderately dissatisfied  
Very dissatisfied  
 
16. Over the past [ADDRESS_769233] you been with your overall sexual  life? 
 
Very satisfied 
Moderately satisfied  
About equally satisfied and dissatisfied 
Moderately dissatisfied  
Very dissatisfied  
 
17. Over the past 4 weeks, how often did you experience discomfort or pain during  
vaginal  penetration?  
 
Did not attempt intercourse 
Almost always or always  
Most times (more than half the time) 
Sometimes (about half the time)  
A few times (less than half the time) 
Almost never or never  
 
18. Over the past 4 weeks, how often did you experience discomfort or pain following  
vaginal  penetration?  
 
Did not attempt intercourse 
Almost always or  always  
Most times (more than half the time) 
Sometimes (abo ut half the time)  
A few times (less than half the time) 
Almost never or never  
 
19. Over the past 4 weeks, how would you rate your level (degree) of discomfort or 
pain during or following vaginal  penetration?  
 
Did not attempt intercourse 
Very high  
High 
Moderate 
Low 
Very low or none at all  
Thank you for completing this questionnaire  
Copyright ©2000  All  Rights  Reserved  Page 5 (of  5) 
Page 1 (of 4)   
 FSFI SCORING APPENDIX  
 
 
Question  Response  Options  
 
1. Over the past [ADDRESS_769234]?  5 = Almost always or always  
4 = Most times (more than half the time) 
3 = Sometimes (about half the time)  
2 = A few times (less than half the time) 
1 = Almost never or never  
 
2. Over the past 4 weeks, how would 
you rate your level (degree) of sexual 
desire or  interest?  5 = Very high 
4 = High  
3 = Moderate  
2 = Low  
1 = Very low or none at all  
 
3. Over the past 4 weeks, how often  did 
you feel sexually aroused ("turned on") 
during sexual activity or  intercourse?  0 = No sexual activity  
5 = Almost always or always  
4 = Most times (more than half the time) 
3 = Sometimes (about half the time)  
2 = A few times (less than half the time) 
1 = Almost never or never  
 
4. Over the past 4 weeks, how  would 
you rate your level of sexual arousal 
("turn on") during sexual activity or 
intercourse?  0 = No sexual activity 
5 = Very hig h 
4 = High  
3 = Moderate  
2 = Low  
1 = Very low or none at all  
 
5. Over the past 4 weeks, how 
confident were you about becoming 
sexually aroused during sexual  activity 
or intercourse?  0 = No sexual activity  
5 = Very high confidence 
4 = High confidence  
3 = Moderate confidence 
2 = Low confidence  
1 = Very low or no confidence  
 
6. Over the past [ADDRESS_769235] you been satisfied with your 
arousal (excitement) during sexual 
activity or  intercourse?  0 = No sexual activity  
5 = Almost always or always  
4 = Most times (more than half the time) 
3 = Sometimes (about half the time)  
2 = A few times (less than half the time) 
1 = Almost never or never  
Page 2 (of 5)   
 7. Over the past 4 weeks, ho w often  did 
you become lubricated ("wet") during 
sexual activity or  intercourse?  0 = No sexual activity  
5 = Almost always or always  
4 = Most times (more than half the time) 
3 = Sometimes (about half the time)  
2 = A few times (less than half the time) 
1 = Almost never or never  
 
8. Over the past 4 weeks, how  difficult 
was it to become lubricated ("wet") 
during sexual activity or  intercourse?  0 = No sexual activity  
1 = Extremely difficult or impossible 
2 = Very difficul t 
3 = Difficult  
4 = Slightly difficult 
5 = Not difficult  
 
9. Over the past 4 weeks, how often did 
you maintain your lubrication 
("wetness") until completion of sexual 
activity or  intercourse?  0 = No sexual activity  
5 = Almo st always or always  
4 = Most times (more than half the time) 
3 = Sometimes (about half the time)  
2 = A few times (less than half the time) 
1 = Almost never or never  
 
10. Over the past 4 weeks, how 
difficult was it to maintain your 
lubrication ("wetness") until completion 
of sexual activity or  intercourse?  0 = No sexual activity  
1 = Extremely difficult or impossible 
2 = Very difficult  
3 = Difficult  
4 = Slightly difficult 
5 = Not difficult  
 
11. Over the past 4 weeks, when you 
had sexual stimulation or intercourse, 
how often did you reach orgasm 
(climax)?  0 = No sexual activity  
5 = Almost always or always  
4 = Most times (more than half the time) 
3 = Sometimes (about half the time)  
2 = A few times (less than half the time) 
1 = Almost never or never  
 
12. Over the past 4 weeks, when you 
had sexual stimulation or intercourse, 
how difficult was it for you to reach 
orgasm (climax)?  0 = No sexual activity  
1 = Extremely difficult or impossible 
2 = Very difficult  
3 = Difficult  
4 = Slightly difficult 
5 = Not difficult  
 
 
 
 
 
 
 
 
 
Page 2 (of 4)  
Page 3 (of 4)   
 13. Over the past 4 weeks, how 
satisfied were you with your ability to 
reach orgasm (climax) during sexual 
activity or  intercourse?  0 = No sexual activity 
5 = Very satisfied  
4 = Moderately satisfied  
3 = About equally satisfied and dissatisfied 
2 = Moderately dissatisfied  
1 = Very dissatisfied  
 
14. Over the past [ADDRESS_769236] you been with the 
amount of emotional closeness during 
sexual activity between you and your 
partner?  0 = No sexual activity 
5 = Very satisfied  
4 = Moderately satisfied  
3 = About equally satisfied and dissatisfied 
2 = Moderately dissatisfied  
1 = Very dissatisfied  
 
15. Over the past [ADDRESS_769237] you been with your 
sexual relationship with your  partner?  5 = Very satisfied  
4 = Moderately satisfied  
3 = About equally satisfied and dissatisfied 
2 = Moderately dissatisfied  
1 = Very dissatisfied  
 
16. Over the past [ADDRESS_769238] you been with your 
overall sexual  life? 5 = Ver y satisfied  
4 = Moderately satisfied  
3 = About equally satisfied and dissatisfied 
2 = Moderately dissatisfied  
1 = Very dissatisfied  
 
17. Over the past 4 weeks, how  often 
did you experience discomfort or pain 
during vaginal  penetration?  0 = Did not attempt intercourse 
1 = Almost always or always  
2 = Most times (more than half the time) 
3 = Sometimes (about half the time)  
4 = A few times (less than half the time) 
5 = Almost never or never  
 
18. Over the past 4 weeks, how  often 
did you experience discomfort or pain 
following vaginal  penetration?  0 = Did not attempt intercourse 
1 = Almost always or always  
2 = Most times (more than half the time) 
3 = Sometimes (about half the time)  
4 = A few times (less than half the time) 
5 = Almost never or never  
 
19. Over the past 4 weeks, how  would 
you rate your level (degree) of 
discomfort or pain during or following 
vaginal  penetration?  0 = Did not attempt intercour se 
1 = Very high  
2 = High  
3 = Moderate  
4 = Low  
5 = Very low or none at all  
 
  
 
FSFI DOMAIN SCORES AND FULL SCALE SCORE  
 
The individual domain scores and full scale (overall) score of the FSFI can be derived from the computational formula 
outlined in the  table  below.  For individual domain scores, add the scores of the individual items that comprise the  domain 
and multiply the sum by [CONTACT_585090]  (see below).  Add the six domain scores to obtain the full scale score .  It 
should be noted that within the individual domains, a domain score of zero indicates that the subject reported having no 
sexual activity during the past month. Subject scores can be entered in the right -hand  column.  
 
 
Domain  Questions  Score 
Range  Factor  Minimum 
Score  Maximum 
Score  Score  
       
Desire  1, 2 1 – 5 0.6 1.2 6.0  
Arousal  3, 4, 5, 6  0 – 5 0.3 0 6.0  
Lubrication  7, 8, 9, 10  0 – 5 0.3 0 6.0  
Orgasm  11, 12, 13  0 – 5 0.4 0 6.0  
Satisfaction  14, 15, 16  0 (or 1) – 5 0.4 0.8 6.0  
Pain 17, 18, 19  0 – 5 0.4 0 6.0  
       
Full Scale Score Range  2.0 36.0  
 
 
 
 
 
 
 
 
 
 
 
 
 
Page 4 (of 4)  
Proprietary and Confidential. Do not reproduce, in whole or in part, without written consent of J3 Bioscience, Inc.   
  
J3 Bioscience, 
Inc. Clinical Investigation Plan and Protocol CI03  
CI03 -CIP 
Rev. 0 2 
Page 59 of 60 A Clinical Investigation to Evaluate Efficacy of the J3  
Bioscience Lubricating Intravaginal Ring VR101 as a 
Personal Lubricant Device in Women  
 
Appendix B  
VR101 Investigational Labeling / 
Instructions for Use  
 
(Note: Appendix B is 11 pages long including this page)  
Proprietary and Confidential. Do not reproduce, in whole or in part, without written consent of J3 Bioscience, Inc.   
  
J3 Bioscience, 
Inc. Labeling  Specification  
VR101 Single -Unit Label 
for devices used in  CLINICAL  
INVESTIGATIONS  LBL 001 
Rev.  01 
Page 1 of 5 
  
 
REVISION LOG  
 
Rev Eff. Date  CO Brief Description of Change  Author  
00 17-03-31 2017 -06 Original approval and implementation  pT 
01 21-01- 
2020  CR- 
0005  Update J3 Bioscience Address, Revised Warning for Pregnancy /  
Breastfeeding  JTC 
     
     
     
     
     
 
 
 
 
 
 
 
 
 
 
Distribution List  
Document Control  
R and D  
Manufacturing  
Quality Assurance  
Regulatory  
Clinical  
Cust. Svc/ Purchasing  
Management  
Lubrizol/ Vesta  
Purchasing  
Control Status of This Document:  
 
Controlled  
Document must be marked as Original, 
Controlled, Uncontrolled or Draft  
Proprietary and Confidential. Do not reproduce, in whole or in part, without written consent of J3 Bioscience, Inc.   
  
J3 Bioscience, 
Inc. Labeling  Specification  
VR101 Single -Unit Label 
for devices used in  CLINICAL  
INVESTIGATIONS  LBL 001 
Rev.  01 
Page 2 of 5 
  
 
1.0 Part Number  LBL 001 
 
2.0 Name [INVESTIGATOR_6731]101 Single -Unit Label - for devices used in clinical  investigations  
 
3.0 Description  
 
Label to be affixed to packaged VR101 devices for exclusive use in clinical 
investigations  
 
4.0 General  Requirements  
 
4.1 Color: black lettering/graphics on white  label  
 
4.2 Description, Label Dimensions, and Graphics (markings) per following  table:  
 
 
Product 
Code  Description 
& 
Label Size Graphic  
LBL 001  Single -Unit 
Pouch Label 
with 
Pressure - 
Sensitive 
Adhesive 
Backing  
3.3” 
X 
4.0”  
(Label Stock: 
Avery PN 
8164)   
VR101 Vaginal Lubrication Ring  
Manufactured by: J3 Bioscience, Inc.  
[ADDRESS_769239], Suite N231, Salt Lake City, Utah [ZIP_CODE]  
 
VR101 is a personal lubrication device for vaginal application intended 
to moisturize and lubricate, to enhance the ease and comfort of 
intimate sexual activity, and supplement the body's natural 
lubrication.  
 
CAUTION: Investigational device limited  to investigational use only. 
CONTRAINDICATIONS : Use is restricted to patients enrolled in VR101 
Clinical Study.  
WARNINGS : For vaginal use only. VR101 is not a contraceptive, does 
not contain a spermicide and does not protect from any sexually - 
transmitted  infections. Keep out of reach of children. Do not ingest or 
place in mouth. If vaginal irritation occurs, discontinue use. If 
symptoms persist, contact [CONTACT_496026]. Do not use if pregnant or 
breast feeding.  
Store at  room  temperature.  LBL 001 R01  2020 -01 
Expi[INVESTIGATOR_5952]:  
SEE INSTRUCTIONS FOR USE  
Proprietary and Confidential. Do not reproduce, in whole or in part, without written consent of J3 Bioscience, Inc.   
  
J3 Bioscience, 
Inc. Labeling  Specification  
VR101 Single -Unit Label 
for devices used in  CLINICAL  
INVESTIGATIONS  LBL 001 
Rev.  01 
Page 3 of 5 
  
 
4.3 Manufacturing  
4.3.1  Label stock will be provided in sheets, 4 labels per  sheet  
4.3.2  Text and Marking will be printed using a laser  printer  
 
4.4 Cosmetics  
4.4.1  Text and markings are to be clear and  legible  
 
5.0 Packag ing and  Labeling  
 
5.1 Paper Stock (Avery  Product)  
5.1.[ADDRESS_769240], or package in clean Zip Lock (or equivalent)  bags  
 
6.[ADDRESS_769241] 
packaging identify item as J3 Bioscience PN 002, Lot Number, PO Number, Quantity, 
and Manufacturing  Date.  
8.1.1   Certificate of Compliance is received with order and has been signed and dated by 
[CONTACT_585091].(Not  Applicable)  
8.1.2  Qualification  Requirements:  
 First Article  Inspection  
 Supplier Survey  
 Vendor Site Visit  
 Material Certification  
 Certification of  Compliance  
 GMP  Certification  
Proprietary and Confidential. Do not reproduce, in whole or in part, without written consent of J3 Bioscience, Inc.   
  
J3 Bioscience, 
Inc. Labeling  Specification  
VR101 Single -Unit Label 
for devices used in  CLINICAL  
INVESTIGATIONS  LBL 001 
Rev.  01 
Page 4 of 5 
  
 
 MSDS  
 Other:     
8.1.3  Inspection Requirements: 
Each lot to be inspected 
Sample Size:  
 AQL 2.5 C =  0 
 100%  
 N = 1 
 Other: Verify Avery Part No. of label  stock  
 Verify Color of printed  label  
 Verify text and markings are as indicated in table appearing in Section 
4.2. 
 
8.1.4  Inspection  Protocol  
[IP_ADDRESS]  Documentation  Verification  
Assure correct Avery Part Number of label stock.  
[IP_ADDRESS]  Material Inspection 
Not required  
[IP_ADDRESS] Acceptance Criteria  
Label roll stock must be correct Avery Part Number 
Text and markings must be as indicated  
Text and markings must not become illegible when attempts are made to rub them off by 
[CONTACT_585092] a thumb while moving thumb across the label.  
 
[ADDRESS_769242] from sources of light and heat until applied to pouches.  
10.0 Acceptable  Suppliers  
NOTE: SUPPLIER IDENTIFICATION IS FOR J3B USE ONLY (NOT TO BE  
DISTRIBUTED TO SUPPLIERS). Acceptable suppliers are to be identified on the 
last (separate) page of the Part Specification. This page is not to be used or 
referenced when obtaining quotes from potential suppliers or copi[INVESTIGATOR_585054].  
Proprietary and Confidential. Do not reproduce, in whole or in part, without written consent of J3 Bioscience, Inc.   
 J3 Bioscience, Inc.  
For INTERNAL USE 
ONLY   
Labeling Sp ecification 
SUPPLIER IDENTIFICATION   
LBL 001 
Rev.  01 
Page 5 of 5  
 
 
Acceptable Suppliers  
Any supplier of Avery Products  
 
 J3 Bioscience, Inc.  
For INTERNAL USE 
ONLY   
Labeling Specification 
SUPPLIER IDENTIFICATION   
LBL 00 2 
Rev. 0 1  
Page 1 of 5 
  
 
REVISION LOG  
 
Rev Eff. Date  CO Brief Description of Change  Author  
00 17-03-31 2017 -06 Original approval and implementation  pT 
01 21-01- 
2020  CR-0005  • Updated Study Contact [CONTACT_585093]02 to  CI03  
• Corrected to reflect non -collection of used rings per CI03 
CIP R01  JTC 
     
     
     
     
     
 
 
 
 
 
 
 
 
 
 
Distribution List  
Document Control  
R and D  
Manufacturing  
Quality Assurance  
Regulatory  
Clinical  
Cust. Svc/ Purchasing  
Management  
Lubrizol/ Vesta  
Purchasing  
Control Status of This Document:  
 
Controlled  
Document must be marked as Original, 
Controlled, Uncontrolled or Draft  
 
  
 
 
1.0 Part Number  LBL 002 
 
2.0 Name [INVESTIGATOR_6731]101 Instructions for use - for devices used in clinical  investigations  
 
3.0 Description  
 
IFU (Instructions for Use) to be affixed to or accompany VR101 devices used in 
CI 02.  
 
4.0 General  Requirements  
 
4.1 Color: black lettering/graphics on white  label  
 
4.2 Description, Label Dimensions, and Graphics (markings) per following  table:  
 
 
Product 
Code  Description 
& 
Label Size  Graphic  
LBL [ADDRESS_769243] 
white paper or on white paper 
with pressure -sensitive adhesive 
backing. Preferred Dimensions 
are 8.5 x 11”  
Other dimensions are 
acceptable, as long as print is > [ADDRESS_769244] in a zip lock -type bag.  
Warnings:  
• Do not use the ring if it appears to be damaged and/or if the package appears open or  damaged.  
• Do not re -insert a ring that you removed or that was expelled if it appears damaged or contaminated. You may 
wash it in clean water and re -insert it if it is  clean.  
VR101 Removal Instructions  
Remove each VR101 ring after [ADDRESS_769245] the used ring in the trash and out of reach of children an d pets. Do not flush the ring in the  toilet.  
5. Insert a new ring after removal of the used ring, according to the instructions provided  above.  
 
 
Warning : Do not re -insert a ring that you removed or that was expelled if it appears damaged or contaminated. You  may 
wash it in clean water and re -insert it if it is clean. Or, use a new ring. Return any rings that were unable to be replaced to 
the clinic during your next visit.  
 
If you have any questions or concerns call the study coordinator:  
 
In Utah:  [PHONE_12112]  In Idaho:  [PHONE_12113]  
 
LBL 002 R01 2020 -01 J3 Bioscience, Inc.  
For INTERNAL USE 
ONLY   
Labeling Specification 
SUPPLIER IDENTIFICATION   
LBL 00 2 
Rev. 0 1  
Page 3 of 5 
 
 
  
 
 
4.3 Manufacturing  
4.3.1 Text and Marking will be printed using a laser printer.  
 
4.4 Cosmetics  
4.4.1 Text and markings are to be clear and legible.  
 
5.0 Packaging and  Labeling  
 
5.1 Paper Stock (plain paper or paper with pressure -sensitive adhesive  backing)  
5.1.[ADDRESS_769246] (paper stock with adhesive backing) or provide as 
inserts with product (plain paper) or independently (plain  paper).  
 
6.[ADDRESS_769247] packaging identify item as J3 Bioscience PN 002, Lot Number, PO Number, 
Quantity, and Manufacturing  Date.  
8.1.1  As appropriate, verify Certificate of Compliance is received with order and has been 
signe d and dated by [CONTACT_585094].  
8.1.2  Qualification  Requirements:  
 First Article  Inspection  
 Supplier Survey  
 Vendor Site Visit  
 Material  Certification  
 Certification of  Compliance  
 GMP  Certification  
 MSDS  J3 Bioscience, Inc.  
For INTERNAL USE 
ONLY   
Labeling Specification 
SUPPLIER IDENTIFICATION   
LBL 00 2 
Rev. 0 1  
Page 4 of 5 
 
 
  
 
 
 Other:    
8.1.3  Inspection Requirements: 
Each lot to be inspected 
Sample Size:  
 AQL 2.5 C =  0 
 100%  
 N = 1 
 Other: Verify Color of printed  label  
 Verify text and markings are as indicated in Section  4.2. 
 
8.1.4  Inspection  Protocol  
[IP_ADDRESS]  Documentation Verification 
Not required  
[IP_ADDRESS]  Material Inspection 
Not required  
[IP_ADDRESS] Acceptance Criteria  
Text and markings must be as indicated  
Text and markings must not become illegible when attempts are made to rub them off by 
[CONTACT_585092] a thumb while moving thumb across the label.  
 
[ADDRESS_769248] from sources of light and heat until used.  
10.0 Acceptable  Suppliers  
NOTE: SUPPLIER IDENTIFICATION IS FOR J3 Bio USE ONLY (NOT TO BE  
DISTRIBUTED TO SUPPLIERS). Acceptable suppliers are to be identified on the 
last (separate) page of the Part Specification. This page is not to be used or 
referenced when obtaining quotes from potential suppliers or copi[INVESTIGATOR_585054].  
Acceptable Suppliers of l abels are any suppliers of Avery Products.  J3 Bioscience, Inc.  
For INTERNAL USE 
ONLY   
Labeling Specification 
SUPPLIER IDENTIFICATION   
LBL [ADDRESS_769249] Assessment  
 
(Note: Appendix C is 14 pages long including this page)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
J3 Bioscience,  Inc. CONFIDENTIAL  
 
 J3 Bioscience, 
Inc. Title:  
Clinical Hazard Assessment  
VR101  Doc. #:  
CHA 01  
Rev: 00 
 
 
 
Rev Eff. Date  
(yymmdd)  CO Brief Description of Change  Author  
00 190325  2019 -03 New Release  pT 
     
     
     
     
     
     
 
Participants in this risk assessment:  
Function  Title Name  
[CONTACT_585103]  R Tyler McCabe, PhD  
R&D/Engineering  Engineer II (Consultant)  Justin Clark, PhD  
Regulatory/ 
Quality  Consultant  Phil Triolo, PhD, RAC  
Clinical  Advisor  Margit Janat -Amsbury, MD  
 
 
Distribution List  
Document Control  
R and D/ Engineering  
Manufacturing  
Quality Assurance  
Regulatory  
Clinical  
Cust. Svc/ Purchasing  
Management  
 
Control Status of This Document:  
 
Original  
Document must be marked as Original, Controlled, Uncontrolled or 
Draft  
 
 J3 Bioscience, 
Inc. Title:  
Clinical Hazard Assessment  
VR101  Doc. #:  
CHA 01  
Rev: [ADDRESS_769250]  Mitigation Method/ 
Verification that Method  
has been Implemented  Verification or Validation that Potential Hazards are Reduced 
to Acceptable Levels and Users are Adequately Informed of  
Residual Risks  
1. Energy Hazards  
Heat exposure  Device deformed or 
damaged  Under anticipated typi[INVESTIGATOR_585055], device materials 
are not known to degrade.  
 
Shelf life studies per P02  R02 VR101 Shelf Life Evaluation  
 
Residual Risk: None to report to end users  
Radiation exposure 
(exposure to x -rays, 
MRI, other 
diagnostic imaging 
procedures)  Material degraded or 
discolored or 
Release rate  altered  Device contains no 
ferromagnetic materials 
(and is therefore MRI 
compatible) and is unlikely 
to be damaged by [CONTACT_585095] -level  
radiation  No validation necessary; radiation exposure is not a risk.  
 
Residual Risk: None to report to end users  
2. Biological Hazards  
High level of 
bioburden 
on product  Infection  Product is manufactured and 
packaged in a controlled 
environment by [CONTACT_585059]13485:2003 -certified and 
FDA QSR -compliant facility. 
Routine monitoring of 
controlled environment  
demonstrates that  Results of Water Activity studies reported in CPTC M18 -5862 
demonstrate that the glycerol -based lubricating and packaging 
solutions do not support microbial growth (A w is < 0.60).  
 
Results of bioburden enumeration studies conducted on 
packaged devices stored for up to [ADDRESS_769251] been  
 
 J3 Bioscience, 
Inc. Title:  
Clinical Hazard Assessment  
VR101  Doc. #:  
CHA 01  
Rev: [ADDRESS_769252]  Mitigation Method/ 
Verification that Method  
has been Implemented  Verification or Validation that Potential Hazards are Reduced 
to Acceptable Levels and Users are Adequately Informed of  
Residual Risks  
  environment is in a state of 
control and the potential for 
device contamination with 
viable organisms is low and 
acceptable.  detected on any packaged VR101 devices. See Bioburden GLP 
Report from NLI Study 1038660 -S01.  
 
Residual Risk: None to report to end users  
Unacceptably high 
level of  
pyrogens on 
product  Fever  Material -mediated pyrogen 
study per WuXi Protocol 
900770 -27 
 
Toxicologic risk 
assessments of substances 
extracted from VR101.  Pyrogenic responses are not a significant concern for devices 
that are placed in the vagina.  
 
Nonetheless, results of a material -mediated pyrogenicity study 
(See GLP Report for NLI Study 113438 -S01) demonstrate that 
the polymeric ring component of VR101 does not elicit a 
pyrogenic response, and a toxicological risk assessment (See 
Table 9 of Gad Consulting Services Report “ Biological Safety 
Assessment of VR101 Lubricating Intravaginal Ring”, dated 18 
January 2019) concludes that the constituent materials of 
VR101 are not known to elicit a pyrogenic response.  
 
Residual Risk: Device is labelled “non -pyrogenic.”  
Device materials 
present an 
unacceptable 
biological risk  Toxic, immunology, or 
otherwise untoward 
biological response  Toxicologic risk 
assessments of substances 
extracted from VR101.  
 
Biocompatibility studies 
performed by [CONTACT_585096]10993 -1 requirements 
and F DA recommendations  Results of biological safety (biocompatibility) studies 
demonstrated low and acceptable biological and toxicological 
risks. See Gad Consulting Services Report “Biological Safety 
Assessment of VR101 Lubricating Intravaginal Ring”, dated 1 8 
January 2019.  
 
No biological or toxicological effects were seen or reported for 
any of the 21 participants in CI01 or 72 participants in CI02,  J3 Bioscience, 
Inc. Title:  
Clinical Hazard Assessment  
VR101  Doc. #:  
CHA 01  
Rev: 00 
 
 
 J3 Bioscience, 
Inc. Title:  
Clinical Hazard Assessment  
VR101  Doc. #:  
CHA 01  
Rev: [ADDRESS_769253]  Mitigation Method/ 
Verification that Method  
has been Implemented  Verification or Validation that Potential Hazards are Reduced 
to Acceptable Levels and Users are Adequately Informed of  
Residual Risks  
   validating the low and acceptable biological and toxicological 
risk associated with VR101 use. See CI02 -R, Section 5.5.1.  
 
Residual Risk: None to report to end users  
3. Environmental Hazards  
Compatibility with 
other devices  Damage to condoms, 
damage to IUDs, damage 
to other IVRs (intravaginal  
rings) or other devices 
placed intravaginally  Condoms: Compatibility of 
VR101 lubricating solution 
evaluated per ASTM D7661 - 
10. Results of studies performed per ASTM D7661 -10 demonstrate 
the compatibility of VR101 lubricating solution with male 
polyurethane and natural rubber latex condoms and female 
FC2 Condoms. See Report R05.  
  Other Intravaginal Rings:  
Residual risk of use of 
VR101 with other 
intravaginally placed 
devices will be 
documented.  Residual Risk: IFU documents that the use of VR101 with other  
intravaginally placed devices has not been investigated.  
  IUD (Intrauterine Device, 
e.g., ParaGard®) Residual 
risk of use of VR101 with 
other intravaginally placed  
devices will be documented  Residual Risk: IFU will document that the use of VR101 with 
other intravaginally placed devices has not been investigated.  
Handling of the  Damage to device,  Risks associated with the  Inspection procedures are in place to assure devices meet  
device  loss of product  transport and handling of  specifications before being released to the marketplace. See  
 cleanliness, leak of  the device are low, as the  Final Release QA Procedure SOP 7.[ADDRESS_769254] or  sterile and, therefore, loss   J3 Bioscience, 
Inc. Title:  
Clinical Hazard Assessment  
VR101  Doc. #:  
CHA 01  
Rev: 00 
 
 
 J3 Bioscience, 
Inc. Title:  
Clinical Hazard Assessment  
VR101  Doc. #:  
CHA 01  
Rev: [ADDRESS_769255]  Mitigation Method/ 
Verification that Method  
has been Implemented  Verification or Validation that Potential Hazards are Reduced 
to Acceptable Levels and Users are Adequately Informed of  
Residual Risks  
 packages, resulting in 
infection or change of 
rate of delivery of 
lubricant  of the integrity of the 
protective packaging is not 
critical to device function. 
Further, the device is 
robust, with no moving 
parts that could be 
damaged and damage to 
the product or packaging 
would be evident to end 
users. Therefore, the risk of 
damage to devices during 
transpo rt is, by [CONTACT_8345], 
inherently low and 
acceptable  VR101 devices are lightweight and have no sharp edges or other 
characteristics that could puncture or otherwise compromise 
their primary packaging. Consequently, no tests were necessary 
to confirm the ability  of the primary packaging to protect the 
devices.  
 
Further damage to the package is obvious to end user and the 
user is instructed to inspect packaging for damage before use, 
and to not use product if damage is apparent.  
 
Residual Risk: The user is instructed to inspect packaging for 
damage before use, and to not use product if damage is 
apparent.  
Adverse storage 
condition  Loss of product 
cleanliness, leakage of 
fluid due to damage to 
product or packages, 
material degradation  See above: Risks associated 
with storage of the device 
in adverse storage 
conditions are low, as the 
device is not provided 
sterile and, therefore, loss 
of the integrity of the 
protective packaging is not 
critical to device function.  Damage to package is obvious to end use r and user is 
instructed to inspect package for damage before use, and to 
not use product if damage is apparent.  
 
Residual Risk: The user is instructed to inspect packaging for 
damage before use, and to not use product if damage is 
apparent.  
 
Residual Risk : The device is labeled with the symbol for “Keep 
dry.”  
4. Labeling Hazards  J3 Bioscience, 
Inc. Title:  
Clinical Hazard Assessment  
VR101  Doc. #:  
CHA 01  
Rev: 00 
 
 
 J3 Bioscience, 
Inc. Title:  
Clinical Hazard Assessment  
VR101  Doc. #:  
CHA 01  
Rev: [ADDRESS_769256]  Mitigation Method/ 
Verification that Method  
has been Implemented  Verification or Validation that Potential Hazards are Reduced 
to Acceptable Levels and Users are Adequately Informed of  
Residual Risks  
Inadequate labeling  Information on label is 
inadequate, lacks clarity 
or readability, and 
results in device misuse.  Inspection of labeling for 
integrity and legibility  
 
Query of users during CI01 
and CI02 on the ability to 
use the device by [CONTACT_585097]01 demonstrated users’ 
ability to follow provided directions and use device correctly 
after reading the IFU and having any concerns clarified by 
[CONTACT_585098].  
 
Responses to Questionnaire used in CI02 demonstrated use rs’ 
ability to follow provided directions and use device correctly 
after reading the IFU without any input from clinicians or 
others. See Report CI02 -R, Section 5.5.3, Claim 2.  
 
Residual Risk: Labels include the symbol for directing the user 
to See Instruc tions for Use.  
Inadequate or 
wrong information 
in IFU  Incorrect use of the 
device  Query of users during CI01 
and CI02 on the ability to 
use the device by [CONTACT_585097]01 demonstrated users’ 
ability to follow provided directions and use device correctly 
after reading the IFU and having any concerns clarified by 
[CONTACT_585098].  
 
Responses to Questionnaire used in CI02 demonstrated users’ 
ability to follow provi ded directions and use device correctly 
after reading the IFU without any input from clinicians or 
others. See Report CI02 -R, Section 5.5.3, Claim 2.  
 
Residual Risk: Labels include the symbol for directing the user 
to See Instructions for Use.  J3 Bioscience, 
Inc. Title:  
Clinical Hazard Assessment  
VR101  Doc. #:  
CHA 01  
Rev: 00 
 
 
 J3 Bioscience, 
Inc. Title:  
Clinical Hazard Assessment  
VR101  Doc. #:  
CHA 01  
Rev: [ADDRESS_769257]  Mitigation Method/ 
Verification that Method  
has been Implemented  Verification or Validation that Potential Hazards are Reduced 
to Acceptable Levels and Users are Adequately Informed of  
Residual Risks  
Missing IFU  IFU not available when 
needed  IFUs are affixed to each 
packaged device.  Final inspection procedures at contract manufacturer assure all 
devices are packaged with instructions for use.  
 
Residual Risk: None to report to end users  
Allergic response to 
natural latex 
present in  packaging  Skin irritation  Neither the packaging or 
device is constructed of 
materials containing natural 
rubber latex.  No verification required, as device is not constructed of 
materials containing natural rubber  latex.  
 
Residual Risk: End user is informed that the device is not 
manufactured using natural rubber  latex.  
Allergic response to 
device materials  Allergic response, 
anaphylactic shock  Device is composed of 
materials that have not 
been shown to elicit an 
allergic response.  
 
Device evaluated for 
sensitization per WuXi 
protocol 900850 -28. Results of Sensitization study NLI 669632 demonstrate that the 
device/device materials are not sensitizers.  
 
Residual Risk: Device is contraindicated for use in individuals 
with known or suspected allergies to polyurethane or glycerol.  
5. Use - and User -related Hazards  
Improper use of 
device  Device not placed 
properly, expulsion  Query of users during CI01 
and CI02 on the ability to 
use the device by [CONTACT_585099].  Responses to Questionnaire used in CI01 demonstrated users’ 
ability to follow provided directions and use device  correctly 
after reading the IFU and having any concerns clarified by 
[CONTACT_585098].  
 
Responses to Questionnaire used in CI02 demonstrated users’ 
ability to follow provided directions and use device correctly 
after reading the IFU without an y input from clinicians or 
others. See Report CI02 -R, Section 5.5.3, Claim 2.  J3 Bioscience, 
Inc. Title:  
Clinical Hazard Assessment  
VR101  Doc. #:  
CHA 01  
Rev: 00 
 
 
 J3 Bioscience, 
Inc. Title:  
Clinical Hazard Assessment  
VR101  Doc. #:  
CHA 01  
Rev: [ADDRESS_769258]  Mitigation Method/ 
Verification that Method  
has been Implemented  Verification or Validation that Potential Hazards are Reduced 
to Acceptable Levels and Users are Adequately Informed of  
Residual Risks  
    
Residual Risk: None to report to end users  
Reuse of 
contaminated 
device  Infection  Query of users during CI01 
and CI02 on the ability to 
use the device by [CONTACT_585099].  Responses to Questionnaire used in CI01 demonstrated users’ 
ability to follow provided directions and use device correctly 
after reading the IFU and having any concerns clarified by 
[CONTACT_585098].  
 
Responses to Questionnaire used in CI02 demonstrated users’ 
ability to follow provided directions and use device correctly 
after reading the IFU without any input from clinicians or 
others. See Report CI02 -R, Section 5.5.3, Claim 2.  
 
Residual Risks: The IFU states that the device is for single use, 
only.  
Residual Risk: Instructions for use state that if a device is 
expelled, it may be rinsed off an d reinserted.  
Physical movement 
of device during 
activities  Irritation (mechanical)  Mechanical tests to assess 
device compressibility (STP 
004.)  
Physical dimensions of the 
device are not significantly 
different from those of 
other currently marketed  
Intravaginal rings.  Results of mechanical tests to assess device compressibility 
(See R02 -A) demonstrate the compressibility of the device is 
comparable to that of clinically acceptable devices.  
The physical dimensions of the device are verified b efore each 
lot is released (See QAP 001).  
 
Residual Risk: None to report to end users.  J3 Bioscience, 
Inc. Title:  
Clinical Hazard Assessment  
VR101  Doc. #:  
CHA 01  
Rev: 00 
 
 
 J3 Bioscience, 
Inc. Title:  
Clinical Hazard Assessment  
VR101  Doc. #:  
CHA 01  
Rev: [ADDRESS_769259]  Mitigation Method/ 
Verification that Method  
has been Implemented  Verification or Validation that Potential Hazards are Reduced 
to Acceptable Levels and Users are Adequately Informed of  
Residual Risks  
Device releases too 
much lubricant  Leakage of vaginal 
fluids/glycerol solution, 
a user inconvenience 
resulting in lesser device 
use and persistence of 
medical conditions  STP-008 is followed to 
assure a consistent release 
rate in vitro.  
In CI01 and CI02, users 
were asked to rate their 
daily experience with the  
ring on a scale of 1 to 9, 
with a score of 5 
representing a participant 
response that VR101 was 
providing the "right 
amount" of lubrication, and 
a score of 9  representing  
"too much" lubrication.  Results of in vitro release studies can be found in R02-D. 
 
In CI01, the mean daily experience score for the entire study 
population was 6.4 indicating that participants, on average, felt 
that the ring was providing sufficient, but marginally more 
lubrication than needed. See Report CI01 -R. 
 
Participants in  CI02 scored the release of lubricant favorably, 
see CI02 -M01.  
 
Residual Risk: None to report to end users  
Device is too rigid  Discomfort resulting in 
decreased or cessation 
of device use and 
persistence of medical 
conditions  Mechanical tests to assess 
device compressibility (STP - 
004.)  
 
In CI01 and CI02,  
participants were 
presented with the 
statement "The ring is 
comfortable to me today," 
and asked to record their 
agreement level on a scale 
of 0 to 4 (where 3 = "Agree  
a Lot" and 4 = "Agree  Results of mechanical tests to assess device compressibility 
(see R02 -A) demonstrate the compressibility of the device 
meets specs and is comparable to that of clinically acceptable 
devices.  
 
For CI01, the mean agreement level of the study population 
range d from 2.8 to 3.6 throughout the study, and was only less 
than 3 ("Agree a Lot") on 1 out of 14 study days. Furthermore, 
when participants were asked at each of the 3 clinical visits 
where the question was posed what they would change about 
VR101 during an d following use, only 1 of 21 participants said 
that they would make the ring softer.  J3 Bioscience, 
Inc. Title:  
Clinical Hazard Assessment  
VR101  Doc. #:  
CHA 01  
Rev: 00 
 
 
 J3 Bioscience, 
Inc. Title:  
Clinical Hazard Assessment  
VR101  Doc. #:  
CHA 01  
Rev: [ADDRESS_769260]  Mitigation Method/ 
Verification that Method  
has been Implemented  Verification or Validation that Potential Hazards are Reduced 
to Acceptable Levels and Users are Adequately Informed of  
Residual Risks  
  Completely") in their 
diaries.  Results of CI02 also indicate that users generally found the ring 
to be comfortable, see CI02 -R, Section 5.5.3, Claim 3).  
 
Residual Risk: None to report to end users  
Device is too 
small/soft  Device expulsion 
resulting in an 
inconvenience to user 
and potential for device 
contamination.  Mechanical tests to assess 
device compressibility (STP 
004.)  
The physical dimensions of 
the device are not 
significantly different from 
other currently marketed 
IVRs.  Results of mechanical tests to assess device compressibility 
(See R02 -A) demonstrate the compressibility of the device 
meets specs and is comparable to that of clinically acceptable 
devices.  
 
During CI01, only one device was expelled during the study of 
21 participants (42 rings were inserted, valida ting that the ring 
isn’t too small for most anticipated users. See Report CI01 -R). 
 
Residual Risk: None to report to end users.  
Device absorbs or 
emits substances 
with unpleasant 
odors or encourages 
the concentration of 
substances with 
unpleasant odors  Unpleasant odor, 
resulting in lesser device 
use and persistence of 
medical conditions  Participants in CI01 were 
asked to comment on odor, 
and reports of malodor 
were classified as adverse 
events in CI02  In CI01, participants were asked if they noticed any unusual 
vaginal odor at any time during the Ring was in place. Most 
participants (16 of 21, 76% of the population) reported "no 
odor at all," while 5 participants reported "a little odor." No 
participants reported noticing "a lot of odor." It should be 
noted that, no attempt was made to assess whether 
participants felt that this odor was related to Ring use, or a 
normal occurrence.  
In CI02, one report of mild malodor was reported in 890 ring 
uses that was deemed “possibly related” to ring use by [CONTACT_462951]. Two other reports of malodor were reported but 
determined to be unrelated to ring use by [CONTACT_45914] (see  
CI02 -R, Section 5.1)  J3 Bioscience, 
Inc. Title:  
Clinical Hazard Assessment  
VR101  Doc. #:  
CHA 01  
Rev: 00 
 
 
 J3 Bioscience, 
Inc. Title:  
Clinical Hazard Assessment  
VR101  Doc. #:  
CHA 01  
Rev: [ADDRESS_769261]  Mitigation Method/ 
Verification that Method  
has been Implemented  Verification or Validation that Potential Hazards are Reduced 
to Acceptable Levels and Users are Adequately Informed of  
Residual Risks  
    
Residual Risk: None to report to end users. Ring -related 
malodor does not represent a harm to patient safety.  
Chemical reaction 
with analytes of 
interest, or 
interaction with 
microbes  Interference with 
laboratory tests leading 
to possible 
misdiagnoses  No clinical assessments of 
the interference of the 
device with laboratory tests 
have been made.  No examinations or laboratory tests whose results could be 
corrupted by [CONTACT_585100]01 or CI02. Reports in the clinical literature st rongly 
indicate that the amount of glycerol present in the vagina will 
not affect relevant lab study results.  
 
Residual Risk: None to report to end users  
Creation of 
environment 
favorable to 
microbial growth  Increased potential for 
infection  Devices are manufactured 
and packaged under clean, 
controlled conditions.  
 
The water activity of VR101 
lubricating solution is low 
and does not support 
microbial growth.  Test results reported  in CPTC M18 -5862 demonstrate that the  
water activity of the VR101 lubricating solution remains at 
levels that do not support microbial growth (a w<0.60) over the 
shelf life of the device.  
 
None of the bioburden study results, reported for packaged 
devices stored for up to [ADDRESS_769262] been retained for additional bioburden 
testing at longer storage durations. See Bioburden GLP Report 
from NLI Study 1038660 -S01 
 
None of the participants in CI01 reported any infections during 
the 3 -week duration  of the study, which included two weeks of 
device use and one week of assessment at the conclusion of 
the 2 weeks of use.  J3 Bioscience, 
Inc. Title:  
Clinical Hazard Assessment  
VR101  Doc. #:  
CHA 01  
Rev: [ADDRESS_769263]  Mitigation Method/ 
Verification that Method  
has been Implemented  Verification or Validation that Potential Hazards are Reduced 
to Acceptable Levels and Users are Adequately Informed of  
Residual Risks  
   One infection was reported by a participant in CI02 which 
resolved when VR101 was removed. The participant continued 
on in the investigation and completed it with no lasting effects.  
 
Residual Risk: None to report to end users  
Material failure due 
to mishandling  Release of ring contents  Tensile test per STP -[ADDRESS_769264] results demonstrate risks associated with 
release of ring contents (lubricating solution) are low and 
acceptable.  
 
No VR101 mechanical failures were reported during CI01 (42 
rings used, each for one week) or CI 02 (a total of 890 devices 
and 275 shams used). See Reports CI01 -R and CI02 -R. 
 
Residual Risk: User is instructed to See Instructions for Use.  J3 Bioscience, 
Inc. Title:  
Clinical Hazard Assessment  
VR101  Doc. #:  
CHA 01  
Rev: 00 
 
 
  J3 Bioscience, 
Inc. Title:  
Clinical Hazard Assessment  
VR101  Doc. #:  
CHA 01  
Rev: [ADDRESS_769265]  Mitigation Method/ 
Verification that Method  
has been Implemented  Verification or Validation that Potential Hazards are Reduced 
to Acceptable Levels and Users are Adequately Informed of  
Residual Risks  
VR101 is difficult to 
remove  Device is a foreign body 
that can induce 
infection  Mechanical tests to assess 
device compressibility (STP - 
004.)  
The physical dimensions of 
the device are not 
significantly different from 
other currently marketed 
IVRs.  
 
Biocompatibility of VR101 
device.  Results of mechanical tests to assess device compressibility 
(See R02 -A) demonstrate the compressibility of the device 
meets specs and is comparable to that of clinically acceptable 
devices.  
 
Biocompatibility test results demonstrate risks associated with a 
retained ring are low and acceptable (See G ad Consulting 
Services Report “Biological Safety Assessment of VR101 
Lubricating Intravaginal Ring”, dated 18 January 2019)  
 
During CI02, 6 of 72 participants had difficulty removing the 
ring.  
 
Residual Risk: IFU contains the following Warning: “Some 
women  may find VR101 difficult to remove. If VR101 removal is 
difficult, a partner may assist. If removal by a partner is difficult, 
not possible, or painful, contact [CONTACT_585101].”  
 
Conclusions  
 
1. All identified risks have been reduced as far as possible and residual risks have been identified to end users in the 
provided  labeling.  
 
2. Review  of the  benefits  derived  by [CONTACT_585102]101  and the risks inherent in  its use results  in a conclusion  that the benefits  of 
device use outweigh the risks inherent in anticipated end -use and misuse  situations.  